<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">BMC Med</journal-id>
<journal-id journal-id-type="iso-abbrev">BMC Med</journal-id>
<journal-title-group>
<journal-title>BMC Medicine</journal-title>
</journal-title-group>
<issn pub-type="epub">1741-7015</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28760142</article-id>
<article-id pub-id-type="pmc">5537940</article-id>
<article-id pub-id-type="publisher-id">916</article-id>
<article-id pub-id-type="doi">10.1186/s12916-017-0916-3</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The renin–angiotensin system: a possible new target for depression</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Vian</surname>
<given-names>João</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Pereira</surname>
<given-names>Círia</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Chavarria</surname>
<given-names>Victor</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Köhler</surname>
<given-names>Cristiano</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stubbs</surname>
<given-names>Brendon</given-names>
</name>
<xref ref-type="aff" rid="Aff5">5</xref>
<xref ref-type="aff" rid="Aff6">6</xref>
<xref ref-type="aff" rid="Aff7">7</xref>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Quevedo</surname>
<given-names>João</given-names>
</name>
<xref ref-type="aff" rid="Aff9">9</xref>
<xref ref-type="aff" rid="Aff10">10</xref>
<xref ref-type="aff" rid="Aff11">11</xref>
<xref ref-type="aff" rid="Aff12">12</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kim</surname>
<given-names>Sung-Wan</given-names>
</name>
<xref ref-type="aff" rid="Aff15">15</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Carvalho</surname>
<given-names>André F.</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Berk</surname>
<given-names>Michael</given-names>
</name>
<xref ref-type="aff" rid="Aff13">13</xref>
<xref ref-type="aff" rid="Aff14">14</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Fernandes</surname>
<given-names>Brisa S.</given-names>
</name>
<address>
<email>brisasf@gmail.com</email>
</address>
<xref ref-type="aff" rid="Aff13">13</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0474 1607</institution-id><institution-id institution-id-type="GRID">grid.418341.b</institution-id><institution>Psychiatry and Mental Health Department, </institution><institution>Centro Hospitalar Lisboa Norte, </institution></institution-wrap>Lisbon, Portugal </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2181 4263</institution-id><institution-id institution-id-type="GRID">grid.9983.b</institution-id><institution></institution><institution>Faculdade de Medicina da Universidade de Lisboa, </institution></institution-wrap>Lisbon, Portugal </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.418476.8</institution-id><institution>Institut de Neuropsiquiatria i Adiccions (INAD), </institution><institution>Parc de Salut Mar (PSM), </institution></institution-wrap>Barcelona, Spain </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2160 0329</institution-id><institution-id institution-id-type="GRID">grid.8395.7</institution-id><institution>Translational Psychiatry Research Group and Department of Clinical Medicine, </institution><institution>Faculty of Medicine, Federal University of Ceará, </institution></institution-wrap>Fortaleza, Brazil </aff>
<aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2299 5510</institution-id><institution-id institution-id-type="GRID">grid.5115.0</institution-id><institution>Health, Social Care and Education, </institution><institution>Anglia Ruskin University, </institution></institution-wrap>Chelmsford, UK </aff>
<aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2322 6764</institution-id><institution-id institution-id-type="GRID">grid.13097.3c</institution-id><institution>Institute of Psychiatry, Psychology and Neuroscience (IoPPN), </institution><institution>King’s College London, </institution></institution-wrap>London, UK </aff>
<aff id="Aff7"><label>7</label>Institute of clinical Research and Education in Medicine (IREM), Padova, Italy </aff>
<aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9439 0839</institution-id><institution-id institution-id-type="GRID">grid.37640.36</institution-id><institution>Physiotherapy Department, </institution><institution>South London and Maudsley NHS Foundation Trust, </institution></institution-wrap>Denmark Hill, London, SE5 8AZ UK </aff>
<aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9206 2401</institution-id><institution-id institution-id-type="GRID">grid.267308.8</institution-id><institution>Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, </institution><institution>McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), </institution></institution-wrap>Houston, TX USA </aff>
<aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9206 2401</institution-id><institution-id institution-id-type="GRID">grid.267308.8</institution-id><institution>Center of Excellence on Mood Disorders, Department of Psychiatry and Behavioral Sciences, </institution><institution>McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), </institution></institution-wrap>Houston, TX USA </aff>
<aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution>Neuroscience Graduate Program, </institution><institution>The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, </institution></institution-wrap>Houston, TX USA </aff>
<aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2150 7271</institution-id><institution-id institution-id-type="GRID">grid.412287.a</institution-id><institution>Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, </institution><institution>University of Southern Santa Catarina (UNESC), </institution></institution-wrap>Criciúma, SC Brazil </aff>
<aff id="Aff13"><label>13</label>Deakin University, IMPACT Strategic Research Centre, School of Medicine, University Hospital Geelong, Barwon Health, Geelong, VIC Australia </aff>
<aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2179 088X</institution-id><institution-id institution-id-type="GRID">grid.1008.9</institution-id><institution>Department of Psychiatry, Orygen the National Centre of Excellence for Youth Mental Health and Orygen Research Centre, and the Florey Institute for Neuroscience and Mental Health, </institution><institution>University of Melbourne, </institution></institution-wrap>Melbourne, VIC Australia </aff>
<aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0356 9399</institution-id><institution-id institution-id-type="GRID">grid.14005.30</institution-id><institution>Department of Psychiatry, </institution><institution>Chonnam National University Medical School, </institution></institution-wrap>Gwangju, Republic of Korea </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>1</day>
<month>8</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>8</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>15</volume>
<elocation-id>144</elocation-id>
<history>
<date date-type="received">
<day>29</day>
<month>3</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>7</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s). 2017</copyright-statement>
<license license-type="OpenAccess">
<license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">Depression remains a debilitating condition with an uncertain aetiology. Recently, attention has been given to the renin–angiotensin system. In the central nervous system, angiotensin II may be important in multiple pathways related to neurodevelopment and regulation of the stress response. Studies of drugs targeting the renin–angiotensin system have yielded promising results. Here, we review the potential beneficial effects of angiotensin blockers in depression and their mechanisms of action. Drugs blocking the angiotensin system have efficacy in several animal models of depression. While no randomised clinical trials were found, case reports and observational studies showed that angiotensin-converting enzyme inhibitors or angiotensin receptor blockers had positive effects on depression, whereas other antihypertensive agents did not. Drugs targeting the renin–angiotensin system act on inflammatory pathways implicated in depression. Both preclinical and clinical data suggest that these drugs possess antidepressant properties. In light of these results, angiotensin system-blocking agents offer new horizons in mood disorder treatment.</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Depression</kwd>
<kwd>Psychiatry</kwd>
<kwd>Inflammation</kwd>
<kwd>Renin–angiotensin system</kwd>
<kwd>Angiotensin</kwd>
<kwd>ATR1</kwd>
<kwd>ATR2</kwd>
<kwd>Mas</kwd>
<kwd>Angiotensin receptor blockers</kwd>
<kwd>Angiotensin-converting enzyme inhibitors</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2017</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Background</title>
<p id="Par2">The pathophysiology of depression remains elusive and current treatments, which focus on traditional pathways (monoamine alterations), are only partially effective. Remission rates in the treatment of depression are only about 30% for those treated with traditional pharmacotherapy, and multiple agents are often required to achieve an adequate level of recovery [<xref ref-type="bibr" rid="CR1">1</xref>] Evidence points to the involvement of neuroinflammation, oxidative and nitrosative stress pathways, mitochondrial dysfunction and neurotrophic signalling in depression [<xref ref-type="bibr" rid="CR2">2</xref>].</p>
<p id="Par3">Recently, the renin–angiotensin system (RAS) was proposed to be implicated in depression, and that blocking this system, either with angiotensin-converting enzyme inhibitors (ACEIs) or with angiotensin II type 1 receptor (AT1R) blockers, would translate into clinical benefits for the depression treatment [<xref ref-type="bibr" rid="CR3">3</xref>–<xref ref-type="bibr" rid="CR7">7</xref>]. Here, we review the literature so far on RAS-targeting drugs in depression.</p>
</sec>
<sec id="Sec2">
<title>Methods</title>
<p id="Par4">A PubMed search was conducted for literature published between January 1974 and June 2017. Search terms included were: depression OR inflammation OR anxiety OR mood AND renin–angiotensin system, angiotensin, ATR1, ATR2, angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, ATR3, ATR4, Mas, and aldosterone. Systematic reviews, randomised controlled trials (RCTs), observational studies, case series and animal studies with an emphasis on the angiotensin system and its role in depression were included. Articles not in English were excluded. The PubMed search was augmented by manually searching the references of key papers and related literature. The results were presented as a narrative review.</p>
</sec>
<sec id="Sec3">
<title>The RAS in the brain</title>
<p id="Par5">The RAS was discovered in the 19<sup>th</sup> Century, after the blood pressure-raising agent renin was first identified in the rabbit kidney [<xref ref-type="bibr" rid="CR8">8</xref>]. In time, the RAS became an established and extensively studied peripheral regulator of blood pressure and renal-mediated body fluid homeostasis, and was discovered to be a central target in clinical hypertension therapy. Renin, a protein synthesised by the juxtaglomerular cells of the kidney, cleaves the polypeptide angiotensinogen to generate angiotensin I (Ang I). This peptide is metabolised to angiotensin II (Ang II) by angiotensin I-converting enzyme (ACE).</p>
<p id="Par6">It was surprising when renin was identified in the dog brain in 1971 [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Subsequently, intracranial Ang II was shown to elevate blood pressure and to promote fluid intake [<xref ref-type="bibr" rid="CR11">11</xref>–<xref ref-type="bibr" rid="CR14">14</xref>], suggesting that angiotensin receptors were present in the brain. The actions of Ang II in the central nervous system are mediated mainly by two receptor types: AT1R and AT2R [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Other receptors, including MAS [<xref ref-type="bibr" rid="CR17">17</xref>], the (pro)renin receptor (PRR) [<xref ref-type="bibr" rid="CR18">18</xref>] and AT4R [<xref ref-type="bibr" rid="CR19">19</xref>], have also recently been identified but their roles remain less well characterised. AT3R was first reported as a new binding site for Ang II in mouse neuroblastoma cell cultures [<xref ref-type="bibr" rid="CR20">20</xref>], but a separate gene for this receptor remains to be sequenced in humans.</p>
<p id="Par7">AT1R mediates most of the peripheral and central actions of Ang II [<xref ref-type="bibr" rid="CR21">21</xref>] and is implicated in multiple pathways related to regulation of the stress response. Stimulating AT1R contributes to the release of inflammatory markers [<xref ref-type="bibr" rid="CR22">22</xref>]. Ang II interacts with AT1Rs, activating the NADPH–oxidase complex [<xref ref-type="bibr" rid="CR23">23</xref>–<xref ref-type="bibr" rid="CR25">25</xref>], the microglial RhoA/Rho kinase pathway [<xref ref-type="bibr" rid="CR26">26</xref>–<xref ref-type="bibr" rid="CR28">28</xref>], NF-kappa B, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). In turn, activated COX-2 forms an intermediate in several key aspects of central nervous system inflammation, and in oxidative and nitrosative stress (see Fig. <xref ref-type="fig" rid="Fig1">1</xref>). AT1R stimulation also releases tumour necrosis factor α (TNF-α) [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>], which is important in several neurodegenerative disorders [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR31">31</xref>–<xref ref-type="bibr" rid="CR33">33</xref>], and regulates activation of the hypothalamic–pituitary–adrenal axis. Stimulation of AT1R in the parvocellular hypothalamic paraventricular nucleus (PVN) by Ang II increases production of corticotrophin-releasing factor [<xref ref-type="bibr" rid="CR34">34</xref>–<xref ref-type="bibr" rid="CR36">36</xref>]. In turn, this spurs adrenocorticotropic hormone secretion in the anterior pituitary gland, starting the stress response cascade. Accordingly, in humans, AT1R blockade downregulates hypothalamic–pituitary–adrenal axis activation [<xref ref-type="bibr" rid="CR37">37</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>Pathways involved in neuronal damage of angiotensin II through AT1 receptor agonism. Ang II, angiotensin II; AT1R, angiotensin II receptor type 1; PGE2, prostaglandin E2; Cox-2, Cyclooxygenase-2; PPAR-γ, peroxisome proliferator-activated receptor gamma; NF-kB, nuclear factor kappa-light-chain-enhancer of activated B cells; iNOS, inducible nitric oxide synthase; NO, nitric oxide; ROS, reactive oxygen species</p></caption><graphic id="MO1" xlink:href="12916_2017_916_Fig1_HTML"></graphic></fig>
</p>
<p id="Par8">Ang II also stimulates the release of aldosterone via AT1R in the adrenal cortex of the kidney [<xref ref-type="bibr" rid="CR38">38</xref>]. Thus, the acronym ‘RAAS’ (as in renin–angiotensin–aldosterone system) is often used. Besides being regulated by Ang II, aldosterone release is also stimulated by adrenocorticotropic hormone and the sympathetic nervous system. The role of aldosterone in the brain has previously been downplayed because its specific intracellular receptor, the mineralocorticoid receptor (MR), shares affinity with cortisol, which circulates at a ~1000-fold higher concentration than aldosterone [<xref ref-type="bibr" rid="CR39">39</xref>]. For a tissue to be sensitive to aldosterone, it must express 11β-hydroxysteroid dehydrogenase type 2 (HSD-2) protein, which degrades cortisol, freeing the MR to the action of aldosterone. HSD-2 has been identified in the brain, mainly in the nucleus of the solitary tract, but also in the PVN [<xref ref-type="bibr" rid="CR40">40</xref>]; regions that also express AT1R. Surprisingly – paralleling the history of angiotensin – aldosterone synthesis was also recognised in the amygdala, hippocampus and hypothalamus of the brain [<xref ref-type="bibr" rid="CR41">41</xref>].</p>
<p id="Par9">AT1R is particularly dense in the anterior pituitary; the circumventricular organs (area postrema; subfornical organ, the vascular organ of lamina terminalis and the median eminence); the lateral geniculate body; inferior olivary nucleus; the nucleus of the solitary tract and in the PVN, the preoptic and the supraoptic nuclei of the hypothalamus [<xref ref-type="bibr" rid="CR42">42</xref>].</p>
<p id="Par10">Modern molecular approaches have revealed that AT2R is also expressed in the adult brain [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. AT2R is involved in neurodevelopment [<xref ref-type="bibr" rid="CR45">45</xref>–<xref ref-type="bibr" rid="CR49">49</xref>] and participates in cell growth inhibition, fetal tissue development, extracellular matrix modulation, neuronal regeneration, apoptosis, cellular differentiation, and, possibly, vasodilation and left ventricular hypertrophy [<xref ref-type="bibr" rid="CR50">50</xref>]. AT2R stimulation exerts neuroprotective effects in ischaemic stroke in rodents [<xref ref-type="bibr" rid="CR51">51</xref>–<xref ref-type="bibr" rid="CR55">55</xref>], and while the underlying mechanism remains to be fully characterised, it seems to partly involve an increase in the anti-inflammatory cytokine interleukin-10 [<xref ref-type="bibr" rid="CR56">56</xref>]. AT2R is particularly dense in the amygdala, caudate putamen, medial geniculate body, globus pallidus, habenula, hypoglossal nucleus, inferior colliculus, inferior olivary nucleus, locus coeruleus, thalamus, and ventral tegmental area [<xref ref-type="bibr" rid="CR42">42</xref>].</p>
<p id="Par11">More components of the RAS such as ACE2, angiotensin-(1–7) and the Mas receptor have recently been identified in the brain. This alternative pathway is sometimes referred to as the non-classical RAS [<xref ref-type="bibr" rid="CR57">57</xref>]. Originally identified in 1986 as an oncogene in mice [<xref ref-type="bibr" rid="CR58">58</xref>], the tumorigenic power of Mas was later discredited and remained an orphan receptor until it was subsequently shown to bind with Ang (1–7) [<xref ref-type="bibr" rid="CR17">17</xref>]. ACE2 can hydrolyse Ang II to produce Ang-(1–7). It can also cleave Ang I, producing Ang-(1–9) with subsequent Ang-(1-7) formation, although with much less efficiency. Mas is thus proposed to be a receptor for Ang-(1-7), with its highest expression in the brain [<xref ref-type="bibr" rid="CR59">59</xref>]. The action of Ang-(1–7) through Mas is thought to influence arachidonic acid production and nitric oxide synthase activation [<xref ref-type="bibr" rid="CR60">60</xref>] (see Fig. <xref ref-type="fig" rid="Fig2">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Pathway from angiotensinogen to AT1, AT2 and Mas receptors. ACE, Angiotensin-converting enzyme</p></caption><graphic id="MO2" xlink:href="12916_2017_916_Fig2_HTML"></graphic></fig>
</p>
<p id="Par12">The recently discovered PRR is highly expressed in the brain [<xref ref-type="bibr" rid="CR18">18</xref>]. Its large extracellular domain binds and captures renin and its almost inactive precursor prorenin, increasing their enzymatic activities [<xref ref-type="bibr" rid="CR61">61</xref>], but it also mimics the actions of AT1R through intracellular signalling [<xref ref-type="bibr" rid="CR62">62</xref>].</p>
<p id="Par13">A specific receptor for angiotensin IV (Ang IV), another less active peptide than Ang II, was first identified in a guinea pig hippocampus [<xref ref-type="bibr" rid="CR19">19</xref>]. It is thought that the identity of AT4R was established when it was discovered that Ang IV is a strong inhibitor of insulin-regulated aminopeptidase (IRAP) [<xref ref-type="bibr" rid="CR63">63</xref>]. IRAP is responsible for oxytocin degradation and, as demonstrated when an injection of Ang IV abolished the antidepressant effects of oxytocin in mice [<xref ref-type="bibr" rid="CR64">64</xref>], is apparently required for its mood effects to take place. Yet recently, discrepancies between Ang IV binding site-antagonist and IRAP inhibitors [<xref ref-type="bibr" rid="CR60">60</xref>], or the unaltered cognitive response of Ang IV in IRAP knockout mice [<xref ref-type="bibr" rid="CR65">65</xref>], have cast doubt on whether IRAP is the only AT4R receptor. Further candidates for the role of AT4R have been proposed [<xref ref-type="bibr" rid="CR42">42</xref>].</p>
<p id="Par14">Ang II is also involved in cerebral blood flow regulation [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Rising circulating Ang II is free to cross into the subfornical organ. This is a circumventricular organ lacking the blood–brain barrier, which, via AT1R, signals the paraventricular nucleus of the hypothalamus to activate the rostral ventrolateral medullary neurons and peripheral sympathetic nerves, thereby raising blood pressure [<xref ref-type="bibr" rid="CR66">66</xref>]. Overstimulation of AT1Rs can lead to endothelial dysfunction [<xref ref-type="bibr" rid="CR67">67</xref>] and neuronal injury and vulnerability caused by cerebrovascular remodelling [<xref ref-type="bibr" rid="CR68">68</xref>–<xref ref-type="bibr" rid="CR72">72</xref>].</p>
<p id="Par15">It is well established that angiotensin receptors are present in the brain, yet the origin of active angiotensin peptides in the brain remains somewhat controversial. Researchers are puzzled because while Ang II is too hydrophilic to cross the blood–brain barrier [<xref ref-type="bibr" rid="CR73">73</xref>], expression of renin in the brain is too low to account for its local synthesis [<xref ref-type="bibr" rid="CR74">74</xref>]. Among the hypotheses advanced to solve this apparent paradox are renin-independent synthesis of angiotensin peptides [<xref ref-type="bibr" rid="CR75">75</xref>]; impaired blood–brain barrier in hypertension leading to Ang II leaking into the cerebrospinal fluid [<xref ref-type="bibr" rid="CR73">73</xref>]; an intracellular form of renin in the brain [<xref ref-type="bibr" rid="CR76">76</xref>] or undetectable renin caused by its sequestration by PRR [<xref ref-type="bibr" rid="CR62">62</xref>]. Although uncertainties persist, targeting the brain RAS or the peripheral RAS cannot be equal because ACEIs that penetrate the blood–brain barrier are superior to non-centrally acting ones in preventing cognitive decline [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>].</p>
</sec>
<sec id="Sec4">
<title>Major depressive disorder (MDD) and neuroinflammation: pre-clinical data</title>
<p id="Par16">Inflammation is essential for restoring homeostasis in stress, infection and injury [<xref ref-type="bibr" rid="CR79">79</xref>]. Hormones and circulating pro-inflammatory cytokines, products of neuronal injury and bacterial endotoxins, activate transcription factors. Activated inflammatory cascades with brain parenchymal microglia and blood-derived infiltrating macrophages also participate [<xref ref-type="bibr" rid="CR80">80</xref>]. A well-regulated central inflammatory chain is fundamental to restore homeostasis, but an exaggerated response can be responsible for chronic inflammation, neuronal damage and a decrease in brain-derived neurotrophic factor [<xref ref-type="bibr" rid="CR81">81</xref>–<xref ref-type="bibr" rid="CR86">86</xref>]. Thus, excess or sustained activation of immune responses augments the risk of disease in vulnerable individuals, and can be important in the pathophysiology of many neurological and psychiatric disorders [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR87">87</xref>–<xref ref-type="bibr" rid="CR96">96</xref>].</p>
<p id="Par17">The inflammatory hypothesis [<xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR98">98</xref>] postulates that depression is the result of altered immune-inflammatory pathways. This leads to increased immune activation, inflammation, nitro-oxidative stress and alteration of the kynurenine pathway, which ultimately causes changes in monoamine levels. MDD is characterised by a low-grade inflammatory state with increased peripheral levels of inflammatory cytokines, and microglial activation [<xref ref-type="bibr" rid="CR98">98</xref>–<xref ref-type="bibr" rid="CR103">103</xref>]. Normalised levels of inflammatory markers are associated with remission of clinical depression [<xref ref-type="bibr" rid="CR104">104</xref>], while persistently elevated levels are associated with a lack of response to antidepressants [<xref ref-type="bibr" rid="CR105">105</xref>]. Elevated levels of inflammatory markers such as C-reactive protein (CRP) may increase the risk of a first episode of depression [<xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR107">107</xref>]. However, a large Mendelian randomisation study found no causal association between increased CRP levels and depression in people with genetically elevated CRP [<xref ref-type="bibr" rid="CR108">108</xref>], and also that inflammation may better stratify those who will or will not benefit from anti-inflammatory treatments [<xref ref-type="bibr" rid="CR109">109</xref>]. More compelling is the strong observation of depressive symptoms induced by interferon-α treatment, both in humans and in animal models [<xref ref-type="bibr" rid="CR110">110</xref>–<xref ref-type="bibr" rid="CR113">113</xref>].</p>
<p id="Par18">Consequently, it has been hypothesised that drugs with anti-inflammatory properties might also demonstrate antidepressant potential. Nonsteroidal anti-inflammatory drugs have shown benefits [<xref ref-type="bibr" rid="CR114">114</xref>, <xref ref-type="bibr" rid="CR115">115</xref>], although no influence was observed in association with antidepressants [<xref ref-type="bibr" rid="CR116">116</xref>]. Cytokine inhibitors were found to improve depression [<xref ref-type="bibr" rid="CR117">117</xref>–<xref ref-type="bibr" rid="CR119">119</xref>] and specific depressive symptoms, such as anxiety [<xref ref-type="bibr" rid="CR120">120</xref>] and fatigue [<xref ref-type="bibr" rid="CR117">117</xref>], among patients with psoriasis [<xref ref-type="bibr" rid="CR117">117</xref>, <xref ref-type="bibr" rid="CR118">118</xref>, <xref ref-type="bibr" rid="CR120">120</xref>] or ankylosing spondylitis [<xref ref-type="bibr" rid="CR119">119</xref>]. This finding is supported by evidence from animal models [<xref ref-type="bibr" rid="CR121">121</xref>]. In an open-label report, aspirin exhibited antidepressive effects, even at low doses [<xref ref-type="bibr" rid="CR122">122</xref>], and may have a more favourable benefit/risk ratio compared with selective COX-2 inhibitors [<xref ref-type="bibr" rid="CR123">123</xref>, <xref ref-type="bibr" rid="CR124">124</xref>]. Epidemiological reports also support antidepressant effects of aspirin [<xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR125">125</xref>]. N-acetylcysteine may also be useful in treating MDD [<xref ref-type="bibr" rid="CR126">126</xref>–<xref ref-type="bibr" rid="CR128">128</xref>]. Statins, which apart from their antiatherosclerotic and cardioprotective effects also display neuroprotective and anti-inflammatory effects [<xref ref-type="bibr" rid="CR129">129</xref>–<xref ref-type="bibr" rid="CR131">131</xref>], showed the potential to produce mood-related benefits [<xref ref-type="bibr" rid="CR132">132</xref>] and are associated with a reduced risk of depression [<xref ref-type="bibr" rid="CR133">133</xref>]. Clinical trials of statins seem to show antidepressant effects in aggregate [<xref ref-type="bibr" rid="CR134">134</xref>]. In a meta-analysis, supplementing the treatment of severe MDD with polyunsaturated fatty acids (PUFAs) was found to be beneficial, even though its role in mild-to-moderate depression or prevention seems limited [<xref ref-type="bibr" rid="CR135">135</xref>].</p>
<p id="Par19">Studies attempting to link depression with genetic variations in the RAS provide additional evidence. Initial reports for the most studied ACE polymorphism (I/D) – the presence or absence of a 287-bp fragment in intron 16 related to ACE serum levels [<xref ref-type="bibr" rid="CR136">136</xref>] – were inconsistent and a meta-analysis showed no significance [<xref ref-type="bibr" rid="CR137">137</xref>, <xref ref-type="bibr" rid="CR138">138</xref>]. However, other single nucleotide polymorphisms have been associated with depression [<xref ref-type="bibr" rid="CR139">139</xref>, <xref ref-type="bibr" rid="CR140">140</xref>], including the GG genotype of ACE A2350G, which also correlated with higher ACE serum activity [<xref ref-type="bibr" rid="CR141">141</xref>]. Recently, seven single nucleotide polymorphisms were significantly tied to late-life depression and cortisol levels under stressful circumstances [<xref ref-type="bibr" rid="CR142">142</xref>]. The AT1R genotype (A1166C) CC is also associated with depression and increased responsiveness to Ang II [<xref ref-type="bibr" rid="CR6">6</xref>], as well as clinical response [<xref ref-type="bibr" rid="CR143">143</xref>, <xref ref-type="bibr" rid="CR144">144</xref>]. Epigenetic mechanisms also appear to be important, as altered methylation of the regulatory region of the ACE gene has been associated with depression [<xref ref-type="bibr" rid="CR145">145</xref>]. ACE polymorphisms even seem able to influence antidepressant response [<xref ref-type="bibr" rid="CR145">145</xref>–<xref ref-type="bibr" rid="CR147">147</xref>], cognitive function after a depression episode in the elderly [<xref ref-type="bibr" rid="CR148">148</xref>, <xref ref-type="bibr" rid="CR149">149</xref>], or suicide behaviour [<xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR151">151</xref>].</p>
<p id="Par20">The role of aldosterone in depression is an emerging area of research, thus regulation of aldosterone by the RAS is another point to take into account. Patients with primary hyperaldosteronism have depressive symptoms [<xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR153">153</xref>]. In animal models, administering aldosterone leads to depressive behaviour [<xref ref-type="bibr" rid="CR154">154</xref>], anxiety [<xref ref-type="bibr" rid="CR155">155</xref>] and anhedonia [<xref ref-type="bibr" rid="CR156">156</xref>]. Eplerone, an aldosterone antagonist, had anxiolytic properties in rats [<xref ref-type="bibr" rid="CR157">157</xref>]. Poorer clinical outcome in MDD is predicted by higher salivary aldosterone [<xref ref-type="bibr" rid="CR158">158</xref>, <xref ref-type="bibr" rid="CR159">159</xref>]. Conversely, MDD patients with suicidal behaviour had lower concentrations of aldosterone compared to suicidal patients without MDD and non-suicidal depressive patients [<xref ref-type="bibr" rid="CR160">160</xref>]. Spironolactone, another MR antagonist, induces a sleep pattern characteristic of melancholic depression and reduces the efficacy of amitriptyline [<xref ref-type="bibr" rid="CR40">40</xref>]. This hints at a non-linear dynamic of aldosterone throughout the MDD episode, prompting its exploration as a biomarker that is able to differentiate depression duration. Indeed, at least in women, higher aldosterone levels are associated with a shorter duration of a depressive episode [<xref ref-type="bibr" rid="CR159">159</xref>], and in an animal model were used to mark the onset of depression [<xref ref-type="bibr" rid="CR161">161</xref>].</p>
<p id="Par21">Taking the above evidence in aggregate, current understanding of the pathophysiology of depression supports the search for novel therapeutics affecting the pathways of inflammation, oxidative biology, apoptosis and neurogenesis. Besides their anti-inflammatory effects, angiotensin receptor blockers (ARBs) and ACEIs have good tolerability, limited side effects and are already widely used drugs approved by the US Food and Drug Administration [<xref ref-type="bibr" rid="CR162">162</xref>, <xref ref-type="bibr" rid="CR163">163</xref>]. Their neuroprotective, anti-inflammatory, vasodilatory [<xref ref-type="bibr" rid="CR164">164</xref>] and microglia activation inhibitory effects [<xref ref-type="bibr" rid="CR29">29</xref>] make them candidates for novel therapeutic targets for inflammatory brain diseases and cognitive disorders [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR165">165</xref>, <xref ref-type="bibr" rid="CR166">166</xref>]. In this regard, interesting data is emerging from animal models.</p>
<p id="Par22">The body of evidence supporting the antidepressant and antianxiety effects of drugs targeting the RAS in animal models is increasing. Mutant mice lacking the angiotensin gene have less depressive-like behaviour in the forced swim test [<xref ref-type="bibr" rid="CR167">167</xref>]. Pharmacologically decreasing the production of Ang II by administering captopril (an ACEI) produces an analogous result [<xref ref-type="bibr" rid="CR168">168</xref>].</p>
<p id="Par23">Blockage of Ang II also leads to antidepressant-like activity in the learned helplessness [<xref ref-type="bibr" rid="CR169">169</xref>] and chronic mild stress paradigms [<xref ref-type="bibr" rid="CR170">170</xref>, <xref ref-type="bibr" rid="CR171">171</xref>], both more valid models than the forced swim test. Preclinical data also suggests a link between the antidepressant effect and a decrease in Ang II activity; AT1R antagonism by its specific blockers losartan [<xref ref-type="bibr" rid="CR3">3</xref>], valsartan [<xref ref-type="bibr" rid="CR171">171</xref>], irbesartan [<xref ref-type="bibr" rid="CR170">170</xref>] and telmisartan [<xref ref-type="bibr" rid="CR172">172</xref>] has similar actions to that caused by ACEIs. As with most antidepressants, use of these blockers also seems to have antianxiety properties. Candesartan [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR173">173</xref>], losartan [<xref ref-type="bibr" rid="CR174">174</xref>, <xref ref-type="bibr" rid="CR175">175</xref>] and captopril [<xref ref-type="bibr" rid="CR176">176</xref>] reduced anxiety behaviour (promoting exploration) in the elevated plus maze test. Nevertheless, enalapril (a non-centrally acting ACEI) was not effective in normotensive rats [<xref ref-type="bibr" rid="CR175">175</xref>].</p>
<p id="Par24">Remarkably, different phenotypes of anxiolytic response to ARBs across different mice strains may be explained by differences in AT1R expression levels [<xref ref-type="bibr" rid="CR177">177</xref>]. Curiously, mood effects were also apparent in an amphetamine-induced model of mania in mice, which candesartan was able to prevent and treat with comparable efficacy to lithium [<xref ref-type="bibr" rid="CR30">30</xref>]. Transgenic rats overexpressing Ang-(1-7) [<xref ref-type="bibr" rid="CR178">178</xref>] or ACE2 [<xref ref-type="bibr" rid="CR179">179</xref>] showed a reduced anxiety phenotype that is seemingly dependent on Mas signalling, since antagonism of Mas reversed the phenotype. Administering Ang-(1-7) was associated with decreased oxidative stress markers in the amygdala [<xref ref-type="bibr" rid="CR180">180</xref>]. The same Mas antagonism also prevented the anxiolytic/antidepressant effect of enalapril in transgenic hypertensive rats [<xref ref-type="bibr" rid="CR181">181</xref>, <xref ref-type="bibr" rid="CR182">182</xref>].</p>
<p id="Par25">These agents seem to influence mood disorders independently of their blood pressure-lowering activity. A study exploring the effect of valsartan in a chronic mild stress model found no change in average blood pressure after a month of treatment, while at the same time registering antianxiety and antidepressant effects [<xref ref-type="bibr" rid="CR171">171</xref>].</p>
<p id="Par26">Animal experiments also support the anti-inflammatory and oxidative stress-reducing effects of these drugs as part of their mechanisms of action. Both irbesartan and fluoxetine decreased levels of thiobarbituric-reactive substances – oxidative stress markers – while increasing catalase and glutathione (antioxidants) and serotonin (5-HT) levels in the brain [<xref ref-type="bibr" rid="CR170">170</xref>]. Valsartan also increased neurogenesis in mice [<xref ref-type="bibr" rid="CR171">171</xref>]. Captopril and perindopril (both centrally acting ACEIs) [<xref ref-type="bibr" rid="CR183">183</xref>], telmisartan [<xref ref-type="bibr" rid="CR183">183</xref>, <xref ref-type="bibr" rid="CR184">184</xref>] and candesartan [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR185">185</xref>, <xref ref-type="bibr" rid="CR186">186</xref>] all show anti-inflammatory effects by reducing microglial activation and levels of inflammatory markers such as nitric oxide and TNF-α.</p>
</sec>
<sec id="Sec5">
<title>Clinical data</title>
<p id="Par27">To date, no RCT has assessed the effects of ACEIs or ARBs in depression. However, observational studies have established a bidirectional link between cardiovascular disorders and depression. Antihypertensive sympatholytic drugs such as reserpine or clonidine can induce depression [<xref ref-type="bibr" rid="CR187">187</xref>–<xref ref-type="bibr" rid="CR189">189</xref>], prompting some to propose that sympathetic nervous system hyperreactivity is a common substrate [<xref ref-type="bibr" rid="CR190">190</xref>, <xref ref-type="bibr" rid="CR191">191</xref>]. It was unclear whether this association was caused by hypertension itself, its treatment, or both [<xref ref-type="bibr" rid="CR192">192</xref>, <xref ref-type="bibr" rid="CR193">193</xref>].</p>
<p id="Par28">A meta-analysis of prospective cohort studies [<xref ref-type="bibr" rid="CR194">194</xref>] found no evidence that hypertension is a risk factor for depression. However, the contrary – that depression increases the risk of developing hypertension – has been suggested [<xref ref-type="bibr" rid="CR195">195</xref>] and confirmed by a meta-analysis [<xref ref-type="bibr" rid="CR196">196</xref>]. In light of all the evidence, the RAS now emerges as a major link between mood and the cardiovascular system.</p>
<p id="Par29">In the early 1980s, several cases reported that captopril might promote mood elevation in patients with MDD [<xref ref-type="bibr" rid="CR197">197</xref>–<xref ref-type="bibr" rid="CR199">199</xref>]. Mood benefits were reported in 9 patients with MDD, and one with bipolar disorder, who were treated with lisinopril (an ACEI) [<xref ref-type="bibr" rid="CR200">200</xref>]. In each case, patients were being treated for hypertension or cardiac heart failure (see Table <xref ref-type="table" rid="Tab1">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Summary of clinical evidence</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2">Studies</th><th>Findings</th><th>Conclusion</th><th>Limitations</th></tr></thead><tbody><tr><td colspan="5">MDD</td></tr><tr><td>Zubenko et al., 1984</td><td>Case report of mood-elevating effect of captopril in three MDD patients</td><td>3 patients:<break></break>72-year-old man with CHF<break></break>44-year-old woman with HT<break></break>67-year-old man with CHF</td><td>Mood elevation of the 3 cases with captopril</td><td>3rd case developed psychotic symptoms</td></tr><tr><td>Deicken, 1986</td><td>Case report of captopril treatment of MDD</td><td>52-year-old man with HT and D</td><td>Improvement of MDD symptoms with captopril</td><td></td></tr><tr><td>Germain &amp; Chouinard, 1988</td><td>Case report of treatment of MDD with captopril</td><td>41-year-old man with D and posterior diagnosis of HT</td><td>Total remission of the MDD episode with captopril</td><td></td></tr><tr><td>Hertzman et al., 2005</td><td>Collection of case reports of lisinopril augmenting antidepressant response (9 MDD + 1 BD)</td><td>Mood elevation of MDD and stabilised mood of the BD patient with lisonopril in patients already on antidepressants or MSs<break></break>All patients being treated for HT</td><td>Improved mood with a combination of antidepressants and lisinopril</td><td></td></tr><tr><td>Rathmann et al., 1999</td><td>Case-control study of 972 diabetic patients</td><td>OR for MDD:<break></break>CCB: OR 2.2 (95% CI: 1.2–4.2)<break></break>BB: OR 2.6 (95% CI: 1.1–7.0)<break></break>ACEI: OR 1.3 (95% CI: 0.8–2.2)</td><td>ACEI associated with reduced risk of MDD</td><td>Screening for MDD made by general practitioners</td></tr><tr><td>Williams et al., 2016</td><td>Case-control study of a 5-year cohort of 961 men with osteoporosis</td><td>Exposure to ACEIs yields reduced risk of MDD (OR: 0.15, 95%<break></break>CI: 0.04–0.51, <italic>P</italic> = 0.003)</td><td>ACE inhibitors were associated with a reduced likelihood for MD onset</td><td>Recall bias, unrecognised confounding and limited generalisability</td></tr><tr><td>Boal et al., 2016</td><td>5-year cohort of 144,660 patients</td><td>ACEI/ARB: 53% decreased risk of MD admissions<break></break>CCB &amp; BB: 2-fold increased risk of MD admissions<break></break>TZ &amp; NT did not attain statistical significance</td><td>ACEI/ARB therapy had a neutral effect (or reduced risk) on MDs</td><td>Results do not include milder levels of MDs treated in the community</td></tr><tr><td colspan="5">Negative findings in MDD</td></tr><tr><td>Habra et al., 2010</td><td>RCT of citalopram in 284<break></break>patients with MDD and coronary disease</td><td>Use of ACEIs associated with mean HAMD response of 1.36 versus 6.42 for non-ACEI use</td><td>ACEI use predicted worse response to antidepressant</td><td>Bias for more severe coronary disease</td></tr><tr><td colspan="5">Mood effects in non-depressed population</td></tr><tr><td>Cohen et al., 1984</td><td>Case report of mood elation with enalapril</td><td>Produced elation in normal volunteers (33% controls and 27% HT subjects)</td><td>Mood elation effect</td><td></td></tr><tr><td>Croog et al., 1986</td><td>RCT on the quality of life of captopril versus methyldopa versus propranolol in 626 male HT patients for 24 weeks</td><td>Captopril: fewer side effects, and better scores for work performance, visual–motor functioning, and measures of life satisfaction versus methyldopa (<italic>P</italic> &lt; 0.05 to &lt; 0.01)<break></break>Captopril: fewer side effects, less sexual dysfunction and greater improvement of measures of general well-being versus propranolol (<italic>P</italic> &lt; 0.05 to &lt; 0.01)</td><td>Captopril group had better scores in tests of general well-being</td><td></td></tr><tr><td>Testa et al., 1993</td><td>RCT on the quality of life of captopril versus enalapril in 379 HT men for 24 weeks</td><td>Captopril: more favourable reports of overall quality of life, general perceived health, vitality, health status, sleep, emotional control (<italic>P</italic> &lt; 0.05)</td><td>The centrally acting ACEI (captopril) showed superior quality of life reports despite equal anti-HT response</td><td></td></tr><tr><td>Johansen et al., 2012</td><td>HUNT study (Norway)<break></break>55,472 HT patients</td><td>OR for depressive symptoms:<break></break>ACEI: OR 0.54, 95% CI 0.28–1.08<break></break>BB: OR 1.20, 95% CI 0.78–1.83<break></break>CCBs: OR 1.04, 95% CI 0.70–1.53</td><td>Depressive symptoms were reduced in ACEI, compared to BB and CCB group</td><td>Self-reported data</td></tr><tr><td>Pavlatou et al., 2008</td><td>Open-label study of candesartan in 17 diabetic patients for ≥ 3 months</td><td>Significant improvement in interpersonal sensitivity (<italic>P</italic> = 0.027) and depression scores (<italic>P</italic> = 0.026)</td><td>Candesartan (an ARB) improves affect</td><td>No control group</td></tr><tr><td colspan="5">Negative findings in mood effects in non-depressed population</td></tr><tr><td>Callender et al., 1983</td><td>Double-blind placebo-controlled crossover trial with captopril in 8 HT patients for 6 weeks</td><td>Mood was slightly lower during captopril administration</td><td>No evidence of mood effects of captopril during the trial</td><td>Small sample and duration of study</td></tr><tr><td>Deary et al., 1991</td><td>Double-blind crossover trial of atenolol and captopril in 18 HT patients for 12 weeks (6 weeks each drug)</td><td>Patients reported feeling less anxious during treatment with atenolol (a BB) (<italic>P</italic> = 0.02).</td><td>A BB was superior to an ACEI in self-reported anxiety</td><td>BBs are known to have an effect in somatic anxiety</td></tr><tr><td>Omvik et al., 1993</td><td>RCT on the quality of life of amlodipine versus enalapril in 461 HT patients for 50 weeks</td><td>Indices on quality of life were unchanged or increased in both groups</td><td>No difference between a CCB and an ACEI in quality of life</td><td></td></tr><tr><td>Fletcher et al., 1992</td><td>RCT on the quality of life of cilazapril versus atenolol versus nifedipine in 540 HT patients for 6 months</td><td>Little difference between quality of life measures in the cilazapril and atenolol groups. Both superior to nifedipine</td><td>No significant differences in quality of life observed between an ACEI and a BB during the trial. Both were superior to a CCB.</td><td>More nifedipine dropouts (17%) compared with atenolol (8%) and cilazapril (5%)</td></tr><tr><td>Weir et al., 1996</td><td>RCT on the quality of life of losartan versus nifedipine in 223 HT patients for 12 weeks</td><td>No significant differences in quality of life reports between groups</td><td>No significant differences in quality of life were observed between an ACEI and a CCB</td><td>Nifedipine had significantly more dropouts (12%) than losartan (5%)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; BB, beta-blockers; BD, bipolar disorder; CCB, calcium channel blockers; CHF, congestive heart failure; CI, confidence interval; D, depression; HAMD, Hamilton Rating Scale for Depression; HT, hypertensive; MDD, major depressive disordersl; MDs, mood disorders; MS, mood stabilisers; NT, non-treatment group; OR, odds ratio; RCT, randomised clinical trial; TZ, thiaziades</p></table-wrap-foot></table-wrap>
</p>
<p id="Par30">In a case-control study of 972 patients from primary care practices, who had both diabetes and a new diagnosis of depression, those exposed to ACEIs in the last 6 months showed a lower odds ratio for depression (OR 1.3, 95% CI: 0.8–2.2) compared to those exposed to beta-blockers (BBs) (OR 2.6, 95% CI: 1.1–7.0) and calcium channel blockers (CCBs) (OR 2.2, 95% CI: 1.2–4.2) [<xref ref-type="bibr" rid="CR201">201</xref>]. In a recent population cohort study, ACEIs decreased the incidence of MDD [<xref ref-type="bibr" rid="CR202">202</xref>]. These results were replicated by Boal <italic>et al.</italic> [<xref ref-type="bibr" rid="CR203">203</xref>], who examined mood-related hospital admissions of 144,660 patients treated with antihypertensive monotherapy for a five-year follow-up. Interestingly, ACEIs and ARBs were associated with the lowest risk of mood disorder admissions (log-rank <italic>P</italic> = 0.006), while CCBs (hazard ratio (HR) = 2.28, [95% CI 1.13–4.58]; <italic>P</italic> = 0.02) and BBs (HR = 2.11, [95% CI 1.12 –3.98]; <italic>P</italic> = 0.02) were associated with increased risk compared to ACEIs and ARBs. There was no significant difference in patients receiving no antihypertensive medication (HR = 1.63 [95% CI 0.94–2.82]; <italic>P</italic> = 0.08), or those taking thiazide diuretics (HR = 1.56 [95% CI 0.65–3.73]; <italic>P</italic> = 0.32).</p>
<p id="Par31">However, in the CREATE trial, a randomised placebo-controlled trial of citalopram in 284 coronary heart disease patients with MDD, the use of ACEIs predicted a worse response to citalopram [<xref ref-type="bibr" rid="CR204">204</xref>]. A possible caveat is that the use of ACEIs may cause bias towards more severe coronary disease, and thus a possible vascular, more refractory type of depression. Another interesting possibility, considering the antidepressant properties of ACEIs, is that their use may have prevented or even treated milder episodes of depression, creating a selection bias for more severe depression. Indeed, we know that an increasingly smaller percentage of patients respond or remit after trying a second or third drug after failing previous treatments [<xref ref-type="bibr" rid="CR205">205</xref>], and that antidepressant-naïve patients improve their Hamilton Depression Rating Scale score more than those taking antidepressants in response to treatment [<xref ref-type="bibr" rid="CR206">206</xref>].</p>
<p id="Par32">The antidepressant effects of ACEIs can be further inferred both by mood effects in the population without a formal diagnosis of MDD, and in studies looking at quality of life. Mood elation was reported in healthy volunteers taking enalapril [<xref ref-type="bibr" rid="CR207">207</xref>]. One RCT found a higher quality of life score was attained in patients taking captopril compared to other classes of antihypertensive drugs, despite similar blood pressure control [<xref ref-type="bibr" rid="CR208">208</xref>]. A head-to-head comparison of captopril (a centrally acting ACEI) and enalapril (a non-centrally acting ACEI) reported no difference in antihypertensive efficacy, but that captopril had a superior effect on quality of life measurements [<xref ref-type="bibr" rid="CR209">209</xref>].</p>
<p id="Par33">In the Norwegian HUNT study [<xref ref-type="bibr" rid="CR192">192</xref>], the depressive symptoms of a large population of 55,472 patients with systemic hypertension taking an ACEI were compared with those of patients with untreated systemic hypertension. Results showed an important trend in favour of the depressive symptom-reducing effects of ACEIs, as assessed by the Hospital Anxiety and Depression Rating Scale (OR 0.54, 95% CI 0.28–1.08). Interestingly, those on BBs (OR 1.20, 95% CI 0.78–1.83) or on CCBs (OR 1.04, 95% CI 0.70–1.53) showed no reduction in depressive symptoms compared to the untreated systemic hypertension group. Again, this suggests that the pharmacological benefits of ACEIs and ARBs in depression are independent of their antihypertensive effects. A small open-label trial of 17 type 2 diabetic patients taking candesartan for at least 3 months found that depression scores were improved [<xref ref-type="bibr" rid="CR210">210</xref>].</p>
<p id="Par34">Nonetheless, there are a few negative reports of the effects of RAS drugs on mood. A small (n = 8), 6-week, double-blind crossover trial found captopril to have no positive effects on mood [<xref ref-type="bibr" rid="CR211">211</xref>]. Another study found the BB atenolol superior to captopril for self-reported anxiety [<xref ref-type="bibr" rid="CR212">212</xref>]. However, BBs are known to affect somatic anxiety, so measuring anxiety might not be an appropriate proxy for mood in this case. In a double-blinded trial of 451 hypertensive patients taking either enalapril or the CCB amlodipine for 38 weeks, no differences were found between the two drugs in terms of quality of life measures [<xref ref-type="bibr" rid="CR213">213</xref>]. Another 6-month double-blind trial with 540 hypertensive patients showed no superiority of cilazapril (an ACEI) over atenolol (a BB) [<xref ref-type="bibr" rid="CR214">214</xref>]. Losartan was also not superior to nifedepine (a CCB) in a 12-week randomised double-blind trial with 223 hypertensive patients [<xref ref-type="bibr" rid="CR215">215</xref>].</p>
</sec>
<sec id="Sec6">
<title>Conclusions</title>
<p id="Par35">A growing body of evidence suggests a role for the angiotensin system in the pathophysiology of MDD. Drugs targeting the RAS reduce oxidative and inflammatory stress and enhance neurogenesis; all documented pathological markers in depression. Despite the heavy burden of depression, new drug development has been underwhelming. While RCTs providing definitive proof are yet to come, available preclinical and clinical data suggest the potential antidepressant properties of ACEIs and ARBs. The search for novel, effective, safe anti-inflammatory drugs that act centrally in the brain are of fundamental interest. Future clinical trials targeting the brain angiotensin system are necessary to verify the usefulness of these agents in treating depression.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>Not applicable.</p>
<sec id="FPar1">
<title>Funding</title>
<p id="Par36">BSF is supported by a postdoctoral fellowship from Deakin University, Australia. CAK is supported by a postdoctoral scholarship from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES; Brazil). AFC is supported by a research fellowship award from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; Brazil). MB is supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (grant number 1059660). The Department of Psychiatry and Behavioral Sciences of McGovern Medical School (USA) funds the Translational Psychiatry Program. The University of Texas Health Science Center at Houston (UTHealth). Laboratory of Neurosciences (Brazil) is a National Institute for Molecular Medicine centre, and a member of the Center of Excellence in Applied Neurosciences of Santa Catarina. Its research is supported by grants from CNPq (JQ), Fundação de Amparo à Pesquisa e Inovação do Estado de Santa Catarina (JQ); Instituto Cérebro e Mente (JQ) and Universidade do Extremo Sul Catarinense (JQ). JQ is a 1A CNPq Research Fellow. MB is supported by an NHMRC Senior Principal Research Fellowship (GNT1059660).</p>
</sec>
<sec id="FPar2">
<title>Availability of data and materials</title>
<p id="Par37">Not applicable.</p>
</sec>
</ack>
<notes notes-type="author-contribution">
<title>Authors’ contributions</title>
<p>All authors participated in the design of this review. JV, CP, and VC performed the systematic review. JV, CP, VC, and BSF wrote the first draft of the manuscript. BSF and MB critically reviewed the first draft of the manuscript. All authors read and approved the final manuscript.</p>
</notes>
<notes notes-type="COI-statement">
<sec id="FPar3">
<title>Ethics approval and consent to participate</title>
<p id="Par38">Not applicable.</p>
</sec>
<sec id="FPar4">
<title>Consent for publication</title>
<p id="Par39">Not applicable.</p>
</sec>
<sec id="FPar5">
<title>Competing interests</title>
<p id="Par40">The authors declare that they have no competing interests.</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jakubovski</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bloch</surname>
<given-names>MH</given-names>
</name>
</person-group>
<article-title>Prognostic subgroups for citalopram response in the STAR*D trial</article-title>
<source/>J Clin Psychiatry
          <year>2014</year>
<volume>75</volume>
<fpage>738</fpage>
<lpage>747</lpage>
<pub-id pub-id-type="doi">10.4088/JCP.13m08727</pub-id>
<pub-id pub-id-type="pmid">24912106</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moylan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Berk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dean</surname>
<given-names>OM</given-names>
</name>
<name>
<surname>Samuni</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>O’Neil</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxidative &amp; nitrosative stress in depression: why so much stress?</article-title>
<source/>Neurosci Biobehav Rev
          <year>2014</year>
<volume>45</volume>
<fpage>46</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2014.05.007</pub-id>
<pub-id pub-id-type="pmid">24858007</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gard</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Mandy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sutcliffe</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Evidence of a possible role of altered angiotensin function in the treatment, but not etiology, of depression</article-title>
<source/>Biol Psychiatry
          <year>1999</year>
<volume>45</volume>
<fpage>1030</fpage>
<lpage>1034</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-3223(98)00101-2</pub-id>
<pub-id pub-id-type="pmid">10386186</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gard</surname>
<given-names>PR</given-names>
</name>
</person-group>
<article-title>The role of angiotensin II in cognition and behaviour</article-title>
<source/>Eur J Pharmacol
          <year>2002</year>
<volume>438</volume>
<fpage>1</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1016/S0014-2999(02)01283-9</pub-id>
<pub-id pub-id-type="pmid">11906704</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gard</surname>
<given-names>PR</given-names>
</name>
</person-group>
<article-title>The brain renin-angiotensin system: a target for novel antidepressants and anxiolytics</article-title>
<source/>Drug Dev Res
          <year>2005</year>
<volume>65</volume>
<fpage>270</fpage>
<lpage>277</lpage>
<pub-id pub-id-type="doi">10.1002/ddr.20028</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saab</surname>
<given-names>YB</given-names>
</name>
<name>
<surname>Gard</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Yeoman</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Mfarrej</surname>
<given-names>B</given-names>
</name>
<name>
<surname>El-Moalem</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ingram</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Renin-angiotensin-system gene polymorphisms and depression</article-title>
<source/>Prog Neuropsychopharmacol Biol Psychiatry
          <year>2007</year>
<volume>31</volume>
<fpage>1113</fpage>
<lpage>1118</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2007.04.002</pub-id>
<pub-id pub-id-type="pmid">17499413</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saavedra</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Pavel</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Angiotensin II AT1 receptor antagonists inhibit the angiotensin-CRF-AVP axis and are potentially useful for the treatment of stress-related and mood disorders</article-title>
<source/>Drug Dev Res
          <year>2005</year>
<volume>65</volume>
<fpage>237</fpage>
<lpage>269</lpage>
<pub-id pub-id-type="doi">10.1002/ddr.20027</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phillips</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Schmidt-Ott</surname>
<given-names>KM</given-names>
</name>
</person-group>
<article-title>The discovery of renin 100 years ago</article-title>
<source/>News Physiol Sci
          <year>1999</year>
<volume>14</volume>
<fpage>271</fpage>
<lpage>274</lpage>
<pub-id pub-id-type="pmid">11390864</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ganten</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Boucher</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Genest</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Renin activity in brain tissue of puppies and adult dogs</article-title>
<source/>Brain Res
          <year>1971</year>
<volume>33</volume>
<fpage>557</fpage>
<lpage>559</lpage>
<pub-id pub-id-type="doi">10.1016/0006-8993(71)90137-5</pub-id>
<pub-id pub-id-type="pmid">4332505</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ganten</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Marquez-Julio</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Granger</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hayduk</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Karsunky</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Boucher</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Renin in dog brain</article-title>
<source/>Am J Physiol
          <year>1971</year>
<volume>221</volume>
<fpage>1733</fpage>
<lpage>1737</lpage>
<pub-id pub-id-type="pmid">4330904</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bickerton</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Buckley</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Evidence for a central mechanism in angiotensin induced hypertension</article-title>
<source/>Exp Biol Med
          <year>1961</year>
<volume>106</volume>
<fpage>834</fpage>
<lpage>836</lpage>
<pub-id pub-id-type="doi">10.3181/00379727-106-26492</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buggy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>AK</given-names>
</name>
</person-group>
<article-title>Angiotensin-induced thirst: effects of third ventricle obstruction and periventricular ablation</article-title>
<source/>Brain Res
          <year>1978</year>
<volume>149</volume>
<fpage>117</fpage>
<lpage>128</lpage>
<pub-id pub-id-type="doi">10.1016/0006-8993(78)90592-9</pub-id>
<pub-id pub-id-type="pmid">656950</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phillips</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Felix</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Specific angiotensin II receptive neurons in the cat subfornical organ</article-title>
<source/>Brain Res
          <year>1976</year>
<volume>109</volume>
<fpage>531</fpage>
<lpage>540</lpage>
<pub-id pub-id-type="doi">10.1016/0006-8993(76)90032-9</pub-id>
<pub-id pub-id-type="pmid">1276933</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Epstein</surname>
<given-names>AN</given-names>
</name>
</person-group>
<article-title>The cerebral ventricles as the avenue for the dipsogenic action of intracranial angiotensin</article-title>
<source/>Brain Res
          <year>1975</year>
<volume>86</volume>
<fpage>399</fpage>
<lpage>418</lpage>
<pub-id pub-id-type="doi">10.1016/0006-8993(75)90891-4</pub-id>
<pub-id pub-id-type="pmid">234776</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Vinh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McCarthy</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Gaspari</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Widdop</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>AT2 receptors: functional relevance in cardiovascular disease</article-title>
<source/>Pharmacol Ther
          <year>2008</year>
<volume>120</volume>
<fpage>292</fpage>
<lpage>316</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharmthera.2008.08.009</pub-id>
<pub-id pub-id-type="pmid">18804122</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oro</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>WG</given-names>
</name>
</person-group>
<article-title>Type 1 angiotensin receptor pharmacology: signaling beyond G proteins</article-title>
<source/>Pharmacol Ther
          <year>2007</year>
<volume>113</volume>
<fpage>210</fpage>
<lpage>226</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharmthera.2006.10.001</pub-id>
<pub-id pub-id-type="pmid">17125841</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santos</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Silva AC</surname>
<given-names>S e</given-names>
</name>
<name>
<surname>Maric</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Machado</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>de Buhr</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor</article-title>
<source/>Mas Proc Natl Acad Sci U S A
          <year>2003</year>
<volume>100</volume>
<fpage>8258</fpage>
<lpage>8263</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1432869100</pub-id>
<pub-id pub-id-type="pmid">12829792</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nguyen</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Delarue</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Burcklé</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bouzhir</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Giller</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sraer</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin</article-title>
<source/>J Clin Invest
          <year>2002</year>
<volume>109</volume>
<fpage>1417</fpage>
<lpage>1427</lpage>
<pub-id pub-id-type="doi">10.1172/JCI0214276</pub-id>
<pub-id pub-id-type="pmid">12045255</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harding</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>VI</given-names>
</name>
<name>
<surname>Miller-Wing</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Hanesworth</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Sardinia</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>KL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of an AII(3–8) [AIV] binding site in guinea pig hippocampus</article-title>
<source/>Brain Res
          <year>1992</year>
<volume>583</volume>
<fpage>340</fpage>
<lpage>343</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-8993(10)80047-2</pub-id>
<pub-id pub-id-type="pmid">1504842</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Inagami</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Identification and characterization of a new binding site for angiotensin II in mouse neuroblastoma neuro-2A cells</article-title>
<source/>Biochem Biophys Res Commun
          <year>1992</year>
<volume>182</volume>
<fpage>388</fpage>
<lpage>394</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-291X(05)80157-3</pub-id>
<pub-id pub-id-type="pmid">1731796</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benicky</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sánchez-Lemus</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Honda</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Orecna</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Angiotensin II AT1 receptor blockade ameliorates brain inflammation</article-title>
<source/>Neuropsychopharmacology
          <year>2011</year>
<volume>36</volume>
<fpage>857</fpage>
<lpage>870</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2010.225</pub-id>
<pub-id pub-id-type="pmid">21150913</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saavedra</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Sánchez-Lemus</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Benicky</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: therapeutic implications</article-title>
<source/>Psychoneuroendocrinology
          <year>2011</year>
<volume>36</volume>
<fpage>1</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="doi">10.1016/j.psyneuen.2010.10.001</pub-id>
<pub-id pub-id-type="pmid">21035950</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joglar</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Rodriguez-Pallares</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rodriguez-Perez</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Rey</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Guerra</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Labandeira-Garcia</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>The inflammatory response in the MPTP model of Parkinson’s disease is mediated by brain angiotensin: relevance to progression of the disease</article-title>
<source/>J Neurochem
          <year>2009</year>
<volume>109</volume>
<fpage>656</fpage>
<lpage>669</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2009.05999.x</pub-id>
<pub-id pub-id-type="pmid">19245663</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodriguez-Pallares</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rey</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Parga</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Muñoz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Guerra</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Labandeira-Garcia</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS</article-title>
<source/>Neurobiol Dis
          <year>2008</year>
<volume>31</volume>
<fpage>58</fpage>
<lpage>73</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2008.03.003</pub-id>
<pub-id pub-id-type="pmid">18499466</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zawada</surname>
<given-names>WM</given-names>
</name>
<name>
<surname>Banninger</surname>
<given-names>GP</given-names>
</name>
<name>
<surname>Thornton</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Marriott</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Cantu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rachubinski</surname>
<given-names>AL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Generation of reactive oxygen species in 1-methyl-4-phenylpyridinium (MPP+) treated dopaminergic neurons occurs as an NADPH oxidase-dependent two-wave cascade</article-title>
<source/>J Neuroinflammation
          <year>2011</year>
<volume>8</volume>
<fpage>129</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-8-129</pub-id>
<pub-id pub-id-type="pmid">21975039</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodriguez-Perez</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Dominguez-Meijide</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lanciego</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Guerra</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Labandeira-Garcia</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson’s disease</article-title>
<source/>Neurobiol Dis
          <year>2013</year>
<volume>58</volume>
<fpage>209</fpage>
<lpage>219</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2013.06.004</pub-id>
<pub-id pub-id-type="pmid">23774254</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tönges</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tatenhorst</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Saal</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Koch</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Szego</surname>
<given-names>ÉM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson’s disease</article-title>
<source/>Brain
          <year>2012</year>
<volume>135</volume>
<fpage>3355</fpage>
<lpage>3370</lpage>
<pub-id pub-id-type="doi">10.1093/brain/aws254</pub-id>
<pub-id pub-id-type="pmid">23087045</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Villar-Cheda</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Valenzuela</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rodriguez-Perez</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Guerra</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Labandeira-Garcia</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration</article-title>
<source/>Neurobiol Aging
          <year>2012</year>
<volume>33</volume>
<fpage>e1</fpage>
<lpage>e11</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2010.08.006</pub-id>
<pub-id pub-id-type="pmid">22244089</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borrajo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rodriguez-Perez</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Diaz-Ruiz</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Guerra</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Labandeira-Garcia</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>Microglial TNF-α mediates enhancement of dopaminergic degeneration by brain angiotensin</article-title>
<source/>Glia
          <year>2014</year>
<volume>62</volume>
<fpage>145</fpage>
<lpage>157</lpage>
<pub-id pub-id-type="doi">10.1002/glia.22595</pub-id>
<pub-id pub-id-type="pmid">24272709</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Souza Gomes</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>de Souza</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Berk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cavalcante</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>de Sousa</surname>
<given-names>FC</given-names>
</name>
<name>
<surname>Budni</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Antimanic-like activity of candesartan in mice: possible involvement of antioxidant, anti-inflammatory and neurotrophic mechanisms</article-title>
<source/>Eur Neuropsychopharmacol
          <year>2015</year>
<volume>25</volume>
<fpage>2086</fpage>
<lpage>2097</lpage>
<pub-id pub-id-type="doi">10.1016/j.euroneuro.2015.08.005</pub-id>
<pub-id pub-id-type="pmid">26321203</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fillit</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Buee</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kalman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Altstiel</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lawlor</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Elevated circulating tumor necrosis factor levels in Alzheimer’s disease</article-title>
<source/>Neurosci Lett
          <year>1991</year>
<volume>129</volume>
<fpage>318</fpage>
<lpage>320</lpage>
<pub-id pub-id-type="doi">10.1016/0304-3940(91)90490-K</pub-id>
<pub-id pub-id-type="pmid">1745413</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hofman</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Hinton</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Merrill</surname>
<given-names>JE</given-names>
</name>
</person-group>
<article-title>Tumor necrosis factor identified in multiple sclerosis brain</article-title>
<source/>J Exp Med
          <year>1989</year>
<volume>170</volume>
<fpage>607</fpage>
<lpage>612</lpage>
<pub-id pub-id-type="doi">10.1084/jem.170.2.607</pub-id>
<pub-id pub-id-type="pmid">2754393</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mogi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Harada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Riederer</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Narabayashi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fujita</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nagatsu</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients</article-title>
<source/>Neurosci Lett
          <year>1994</year>
<volume>165</volume>
<fpage>208</fpage>
<lpage>210</lpage>
<pub-id pub-id-type="doi">10.1016/0304-3940(94)90746-3</pub-id>
<pub-id pub-id-type="pmid">8015728</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aguilera</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Scott Young</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Kiss</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bathia</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Direct regulation of hypothalamic corticotropin-releasing-hormone neurons by angiotensin II</article-title>
<source/>Neuroendocrinology
          <year>1995</year>
<volume>61</volume>
<fpage>437</fpage>
<lpage>444</lpage>
<pub-id pub-id-type="doi">10.1159/000126866</pub-id>
<pub-id pub-id-type="pmid">7783857</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sumitomo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Suda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nakano</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tozawa</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Demura</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Angiotensin II increases the corticotropin-releasing factor messenger ribonucleic acid level in the rat hypothalamus</article-title>
<source/>Endocrinology
          <year>1991</year>
<volume>128</volume>
<fpage>2248</fpage>
<lpage>2252</lpage>
<pub-id pub-id-type="doi">10.1210/endo-128-5-2248</pub-id>
<pub-id pub-id-type="pmid">1850346</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aguilera</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kiss</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Increased expression of type 1 angiotensin II receptors in the hypothalamic paraventricular nucleus following stress and glucocorticoid administration</article-title>
<source/>J Neuroendocrinol
          <year>1995</year>
<volume>7</volume>
<fpage>775</fpage>
<lpage>783</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2826.1995.tb00714.x</pub-id>
<pub-id pub-id-type="pmid">8563720</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wincewicz</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Juchniewicz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Waszkiewicz</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Braszko</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<article-title>Angiotensin II type 1 receptor blockade by telmisartan prevents stress-induced impairment of memory via HPA axis deactivation and up-regulation of brain-derived neurotrophic factor gene expression</article-title>
<source/>Pharmacol Biochem Behav
          <year>2016</year>
<volume>148</volume>
<fpage>108</fpage>
<lpage>118</lpage>
<pub-id pub-id-type="doi">10.1016/j.pbb.2016.06.010</pub-id>
<pub-id pub-id-type="pmid">27375198</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balla</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Baukal</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Catt</surname>
<given-names>KJ</given-names>
</name>
</person-group>
<article-title>Angiotensin II receptor subtypes and biological responses in the adrenal cortex and medulla</article-title>
<source/>Mol Pharmacol
          <year>1991</year>
<volume>40</volume>
<fpage>401</fpage>
<lpage>406</lpage>
<pub-id pub-id-type="pmid">1654513</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geerling</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Loewy</surname>
<given-names>AD</given-names>
</name>
</person-group>
<article-title>Aldosterone in the brain</article-title>
<source/>Am J Physiol Ren Physiol
          <year>2009</year>
<volume>297</volume>
<fpage>F559</fpage>
<lpage>F576</lpage>
<pub-id pub-id-type="doi">10.1152/ajprenal.90399.2008</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murck</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Schüssler</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Steiger</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Renin-angiotensin-aldosterone system: the forgotten stress hormone system: relationship to depression and sleep</article-title>
<source/>Pharmacopsychiatry
          <year>2012</year>
<volume>45</volume>
<fpage>83</fpage>
<lpage>95</lpage>
<pub-id pub-id-type="doi">10.1055/s-0031-1291346</pub-id>
<pub-id pub-id-type="pmid">22290200</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gomez-Sanchez</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>MY</given-names>
</name>
<name>
<surname>Cozza</surname>
<given-names>EN</given-names>
</name>
<name>
<surname>Morita</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Foecking</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Gomez-Sanchez</surname>
<given-names>EP</given-names>
</name>
</person-group>
<article-title>Aldosterone biosynthesis in the rat brain</article-title>
<source/>Endocrinology
          <year>1997</year>
<volume>138</volume>
<fpage>3369</fpage>
<lpage>3373</lpage>
<pub-id pub-id-type="doi">10.1210/endo.138.8.5326</pub-id>
<pub-id pub-id-type="pmid">9231789</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wright</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Harding</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Brain renin-angiotensin - a new look at an old system</article-title>
<source/>Prog Neurobiol
          <year>2011</year>
<volume>95</volume>
<fpage>49</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="doi">10.1016/j.pneurobio.2011.07.001</pub-id>
<pub-id pub-id-type="pmid">21777652</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Kloet</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ludin</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Pioquinto</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Hiller</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reporter mouse strain provides a novel look at angiotensin type-2 receptor distribution in the central nervous system</article-title>
<source/>Brain Struct Funct
          <year>2016</year>
<volume>221</volume>
<fpage>891</fpage>
<lpage>912</lpage>
<pub-id pub-id-type="doi">10.1007/s00429-014-0943-1</pub-id>
<pub-id pub-id-type="pmid">25427952</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Developmental expression patterns for angiotensin receptors in mouse skin and brain</article-title>
<source/>J Renin Angiotensin Aldosterone Syst
          <year>2014</year>
<volume>15</volume>
<fpage>139</fpage>
<lpage>149</lpage>
<pub-id pub-id-type="doi">10.1177/1470320312467557</pub-id>
<pub-id pub-id-type="pmid">23204186</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mao</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Development of fetal brain renin-angiotensin system and hypertension programmed in fetal origins</article-title>
<source/>Prog Neurobiol
          <year>2009</year>
<volume>87</volume>
<fpage>252</fpage>
<lpage>263</lpage>
<pub-id pub-id-type="doi">10.1016/j.pneurobio.2008.12.001</pub-id>
<pub-id pub-id-type="pmid">19428956</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meffert</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stoll</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Steckelings</surname>
<given-names>UM</given-names>
</name>
<name>
<surname>Bottari</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Unger</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells</article-title>
<source/>Mol Cell Endocrinol
          <year>1996</year>
<volume>122</volume>
<fpage>59</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="doi">10.1016/0303-7207(96)03873-7</pub-id>
<pub-id pub-id-type="pmid">8898348</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Mogi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tsukuda</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tomochika</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Iwanami</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Min</surname>
<given-names>LJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Angiotensin II-induced neural differentiation via angiotensin II type 2 (AT2) receptor-MMS2 cascade involving interaction between AT2 receptor-interacting protein and Src homology 2 domain-containing protein-tyrosine phosphatase 1</article-title>
<source/>Mol Endocrinol
          <year>2007</year>
<volume>21</volume>
<fpage>499</fpage>
<lpage>511</lpage>
<pub-id pub-id-type="doi">10.1210/me.2006-0005</pub-id>
<pub-id pub-id-type="pmid">17068200</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stroth</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Meffert</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gallinat</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Unger</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Angiotensin II and NGF differentially influence microtubule proteins in PC12W cells: role of the AT2 receptor</article-title>
<source/>Mol Brain Res
          <year>1998</year>
<volume>53</volume>
<fpage>187</fpage>
<lpage>195</lpage>
<pub-id pub-id-type="doi">10.1016/S0169-328X(97)00298-2</pub-id>
<pub-id pub-id-type="pmid">9473667</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gendron</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Laflamme</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rivard</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Asselin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Payet</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Gallo-Payet</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Signals from the AT2 (angiotensin type 2) receptor of angiotensin II inhibit p21ras and activate MAPK (mitogen-activated protein kinase) to induce morphological neuronal differentiation in NG108-15 cells</article-title>
<source/>Mol Endocrinol
          <year>1999</year>
<volume>13</volume>
<fpage>1615</fpage>
<lpage>1626</lpage>
<pub-id pub-id-type="doi">10.1210/mend.13.9.0344</pub-id>
<pub-id pub-id-type="pmid">10478850</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cernes</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mashavi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zimlichman</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Differential clinical profile of candesartan compared to other angiotensin receptor blockers</article-title>
<source/>Vasc Health Risk Man
          <year>2011</year>
<volume>7</volume>
<fpage>749</fpage>
<lpage>759</lpage>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alhusban</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fouda</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Bindu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ishrat</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Soliman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fagan</surname>
<given-names>SC</given-names>
</name>
</person-group>
<article-title>Compound 21 is pro-angiogenic in the brain and results in sustained recovery after ischemic stroke</article-title>
<source/>J Hypertens
          <year>2015</year>
<volume>33</volume>
<fpage>170</fpage>
<lpage>180</lpage>
<pub-id pub-id-type="doi">10.1097/HJH.0000000000000364</pub-id>
<pub-id pub-id-type="pmid">25304472</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joseph</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Mecca</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Regenhardt</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Bennion</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Rodríguez</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Desland</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The angiotensin type 2 receptor agonist Compound 21 elicits cerebroprotection in endothelin-1 induced ischemic stroke</article-title>
<source/>Neuropharmacology
          <year>2014</year>
<volume>81</volume>
<fpage>134</fpage>
<lpage>141</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2014.01.044</pub-id>
<pub-id pub-id-type="pmid">24508710</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCarthy</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Vinh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Hallberg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Alterman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Callaway</surname>
<given-names>JK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes neuroprotection in conscious hypertensive rats</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<pub-id pub-id-type="doi">10.1371/journal.pone.0095762</pub-id>
<pub-id pub-id-type="pmid">24752645</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Min</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Mogi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tsukuda</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jing</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ohshima</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nakaoka</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Direct stimulation of angiotensin II type 2 receptor initiated after stroke ameliorates ischemic brain damage</article-title>
<source/>Am J Hypertens
          <year>2014</year>
<volume>27</volume>
<fpage>1036</fpage>
<lpage>1044</lpage>
<pub-id pub-id-type="doi">10.1093/ajh/hpu015</pub-id>
<pub-id pub-id-type="pmid">24572705</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwengel</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Namsolleck</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lucht</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Clausen</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Lambertsen</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Valero-Esquitino</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Angiotensin AT2-receptor stimulation improves survival and neurological outcome after experimental stroke in mice</article-title>
<source/>J Mol Med (Berl)
          <year>2016</year>
<volume>94</volume>
<fpage>957</fpage>
<lpage>966</lpage>
<pub-id pub-id-type="doi">10.1007/s00109-016-1406-3</pub-id>
<pub-id pub-id-type="pmid">26983606</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fouda</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Pillai</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Dhandapani</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Ergul</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fagan</surname>
<given-names>SC</given-names>
</name>
</person-group>
<article-title>Role of interleukin-10 in the neuroprotective effect of the Angiotensin type 2 receptor agonist, Compound 21, after ischemia/reperfusion injury</article-title>
<source/>Eur J Pharmacol
          <year>2017</year>
<volume>799</volume>
<fpage>128</fpage>
<lpage>134</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejphar.2017.02.016</pub-id>
<pub-id pub-id-type="pmid">28192099</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mascolo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sessa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Scavone</surname>
<given-names>C</given-names>
</name>
<name>
<surname>De Angelis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vitale</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Berrino</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>New and old roles of the peripheral and brain renin–angiotensin–aldosterone system (RAAS): focus on cardiovascular and neurological diseases</article-title>
<source/>Int J Cardiol
          <year>2017</year>
<volume>227</volume>
<fpage>734</fpage>
<lpage>742</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijcard.2016.10.069</pub-id>
<pub-id pub-id-type="pmid">27823897</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Waitches</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Birchmeier</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Fasano</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Wigler</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains</article-title>
<source/>Cell
          <year>1986</year>
<volume>45</volume>
<fpage>711</fpage>
<lpage>719</lpage>
<pub-id pub-id-type="doi">10.1016/0092-8674(86)90785-3</pub-id>
<pub-id pub-id-type="pmid">3708691</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karnik</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Unal</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kemp</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Tirupula</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Eguchi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Vanderheyden</surname>
<given-names>PM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin receptors: interpreters of pathophysiological angiotensinergic stimuli</article-title>
<source/>Pharmacol Rev
          <year>2015</year>
<volume>67</volume>
<fpage>754</fpage>
<lpage>819</lpage>
<pub-id pub-id-type="doi">10.1124/pr.114.010454</pub-id>
<pub-id pub-id-type="pmid">26315714</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Karnik</surname>
<given-names>SS</given-names>
</name>
</person-group>
<article-title>Angiotensin receptors: structure, function, signaling and clinical applications</article-title>
<source/>J Cell Signal
          <year>2016</year>
<volume>1</volume>
<fpage>1</fpage>
<lpage>8</lpage>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>DD</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>The critical role of the central nervous system (pro)renin receptor in regulating systemic blood pressure</article-title>
<source/>Pharmacol Ther
          <year>2016</year>
<volume>164</volume>
<fpage>126</fpage>
<lpage>134</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharmthera.2016.04.006</pub-id>
<pub-id pub-id-type="pmid">27113409</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cuadra</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Sumners</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Raizada</surname>
<given-names>MK</given-names>
</name>
</person-group>
<article-title>A current view of brain renin-angiotensin system: is the (pro)renin receptor the missing link?</article-title>
<source/>Pharmacol Ther
          <year>2010</year>
<volume>125</volume>
<fpage>27</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharmthera.2009.07.007</pub-id>
<pub-id pub-id-type="pmid">19723538</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lew</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Mustafa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McDowall</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Chai</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Albiston</surname>
<given-names>AL</given-names>
</name>
</person-group>
<article-title>Angiotensin AT4 ligands are potent, competitive inhibitors of insulin regulated aminopeptidase (IRAP)</article-title>
<source/>J Neurochem
          <year>2003</year>
<volume>86</volume>
<fpage>344</fpage>
<lpage>350</lpage>
<pub-id pub-id-type="doi">10.1046/j.1471-4159.2003.01852.x</pub-id>
<pub-id pub-id-type="pmid">12871575</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loyens</surname>
<given-names>E</given-names>
</name>
<name>
<surname>De Bundel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Demaegdt</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Chai</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Vanderheyden</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Michotte</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Antidepressant-like effects of oxytocin in mice are dependent on the presence of insulin-regulated aminopeptidase</article-title>
<source/>Int J Neuropsychopharmacol
          <year>2013</year>
<volume>16</volume>
<fpage>1153</fpage>
<lpage>1163</lpage>
<pub-id pub-id-type="doi">10.1017/S1461145712001149</pub-id>
<pub-id pub-id-type="pmid">23177092</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Albiston</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Fernando</surname>
<given-names>RN</given-names>
</name>
<name>
<surname>Yeatman</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Burns</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Daswani</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gene knockout of insulin-regulated aminopeptidase: Loss of the specific binding site for angiotensin IV and age-related deficit in spatial memory</article-title>
<source/>Neurobiol Learn Mem
          <year>2010</year>
<volume>93</volume>
<fpage>19</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1016/j.nlm.2009.07.011</pub-id>
<pub-id pub-id-type="pmid">19660563</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Killinger</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Horiuchi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dampney</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Baroreceptor reflex modulation by circulating angiotensin II is mediated by AT1 receptors in the nucleus tractus solitarius</article-title>
<source/>Am J Physiol Regul Integr Comp Physiol
          <year>2007</year>
<volume>293</volume>
<fpage>R2267</fpage>
<lpage>R2278</lpage>
<pub-id pub-id-type="doi">10.1152/ajpregu.00267.2007</pub-id>
<pub-id pub-id-type="pmid">17855497</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Savoia</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schiffrin</surname>
<given-names>EL</given-names>
</name>
</person-group>
<article-title>Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions</article-title>
<source/>Clin Sci (Lond)
          <year>2007</year>
<volume>112</volume>
<fpage>375</fpage>
<lpage>384</lpage>
<pub-id pub-id-type="doi">10.1042/CS20060247</pub-id>
<pub-id pub-id-type="pmid">17324119</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozacmak</surname>
<given-names>VH</given-names>
</name>
<name>
<surname>Sayan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Cetin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Akyildiz-Igdem</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>AT1 receptor blocker candesartan-induced attenuation of brain injury of rats subjected to chronic cerebral hypoperfusion</article-title>
<source/>Neurochem Res
          <year>2007</year>
<volume>32</volume>
<fpage>1314</fpage>
<lpage>1321</lpage>
<pub-id pub-id-type="doi">10.1007/s11064-007-9305-1</pub-id>
<pub-id pub-id-type="pmid">17401654</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ando</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Macova</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Imboden</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Saavedra</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats</article-title>
<source/>Stroke
          <year>2004</year>
<volume>35</volume>
<fpage>1726</fpage>
<lpage>1731</lpage>
<pub-id pub-id-type="doi">10.1161/01.STR.0000129788.26346.18</pub-id>
<pub-id pub-id-type="pmid">15143297</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishimura</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hoe</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Saavedra</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Chronic peripheral administration of the angiotensin II AT1 receptor antagonist Candesartan blocks brain AT1 receptors</article-title>
<source/>Brain Res
          <year>2000</year>
<volume>871</volume>
<fpage>29</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-8993(00)02377-5</pub-id>
<pub-id pub-id-type="pmid">10882779</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamakawa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Jezova</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ando</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Saavedra</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Normalization of endothelial and inducible nitric oxide synthase expression in brain microvessels of spontaneously hypertensive rats by angiotensin II AT1 receptor inhibition</article-title>
<source/>J Cereb Blood Flow Metab
          <year>2003</year>
<volume>23</volume>
<fpage>371</fpage>
<lpage>380</lpage>
<pub-id pub-id-type="doi">10.1097/01.WCB.0000047369.05600.03</pub-id>
<pub-id pub-id-type="pmid">12621312</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ando</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Macova</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Saavedra</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Angiotensin II AT1 receptor blockade abolishes brain microvascular inflammation and heat shock protein responses in hypertensive rats</article-title>
<source/>J Cereb Blood Flow Metab
          <year>2005</year>
<volume>25</volume>
<fpage>878</fpage>
<lpage>886</lpage>
<pub-id pub-id-type="doi">10.1038/sj.jcbfm.9600082</pub-id>
<pub-id pub-id-type="pmid">15729290</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Biancardi</surname>
<given-names>VC</given-names>
</name>
<name>
<surname>Stern</surname>
<given-names>JE</given-names>
</name>
</person-group>
<article-title>Compromised blood-brain barrier permeability: novel mechanism by which circulating angiotensin II signals to sympathoexcitatory centres during hypertension</article-title>
<source/>J Physiol
          <year>2016</year>
<volume>594</volume>
<fpage>1591</fpage>
<lpage>1600</lpage>
<pub-id pub-id-type="doi">10.1113/JP271584</pub-id>
<pub-id pub-id-type="pmid">26580484</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saavedra</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities</article-title>
<source/>Cell Mol Neurobiol
          <year>2005</year>
<volume>25</volume>
<fpage>485</fpage>
<lpage>512</lpage>
<pub-id pub-id-type="doi">10.1007/s10571-005-4011-5</pub-id>
<pub-id pub-id-type="pmid">16075377</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Thiel</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Góes Martini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Te Riet</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Severs</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Uijl</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Garrelds</surname>
<given-names>IM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Brain renin–angiotensin system: does It exist?</article-title>
<source/>Hypertension
          <year>2017</year>
<volume>69</volume>
<fpage>1136</fpage>
<lpage>1144</lpage>
<pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.116.08922</pub-id>
<pub-id pub-id-type="pmid">28396529</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grobe</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sigmund</surname>
<given-names>CD</given-names>
</name>
</person-group>
<article-title>An intracellular renin-angiotensin system in neurons: fact, hypothesis, or fantasy</article-title>
<source/>Physiology (Bethesda)
          <year>2008</year>
<volume>23</volume>
<fpage>187</fpage>
<lpage>193</lpage>
<pub-id pub-id-type="doi">10.1152/physiol.00002.2008</pub-id>
<pub-id pub-id-type="pmid">18697992</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohrui</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tomita</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sato-Nakagawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Matsui</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Maruyama</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Niwa</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression</article-title>
<source/>Neurology
          <year>2004</year>
<volume>63</volume>
<fpage>1324</fpage>
<lpage>1325</lpage>
<pub-id pub-id-type="doi">10.1212/01.WNL.0000140705.23869.E9</pub-id>
<pub-id pub-id-type="pmid">15477567</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sink</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Leng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Williamson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kritchevsky</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Yaffe</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kuller</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study</article-title>
<source/>Arch Intern Med
          <year>2009</year>
<volume>169</volume>
<fpage>1195</fpage>
<lpage>1202</lpage>
<pub-id pub-id-type="doi">10.1001/archinternmed.2009.175</pub-id>
<pub-id pub-id-type="pmid">19597068</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yong</surname>
<given-names>VW</given-names>
</name>
<name>
<surname>Rivest</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Taking advantage of the systemic immune system to cure brain diseases</article-title>
<source/>Neuron
          <year>2009</year>
<volume>64</volume>
<fpage>55</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2009.09.035</pub-id>
<pub-id pub-id-type="pmid">19840549</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Licinio</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>ML</given-names>
</name>
</person-group>
<article-title>Pathways and mechanisms for cytokine signaling of the central nervous system</article-title>
<source/>J Clin Invest
          <year>1997</year>
<volume>100</volume>
<fpage>2941</fpage>
<lpage>2947</lpage>
<pub-id pub-id-type="doi">10.1172/JCI119846</pub-id>
<pub-id pub-id-type="pmid">9399938</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brietzke</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Stertz</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fernandes</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Kauer-Sant'anna</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mascarenhas</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Escosteguy Vargas</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder</article-title>
<source/>J Affect Disord
          <year>2009</year>
<volume>116</volume>
<fpage>214</fpage>
<lpage>217</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2008.12.001</pub-id>
<pub-id pub-id-type="pmid">19251324</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandes</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Molendijk</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Köhler</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Soares</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Leite</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Machado-Vieira</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies</article-title>
<source/>BMC Med
          <year>2015</year>
<volume>13</volume>
<fpage>289</fpage>
<pub-id pub-id-type="doi">10.1186/s12916-015-0529-7</pub-id>
<pub-id pub-id-type="pmid">26621529</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Oliveira</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Ceresér</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Fernandes</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Kauer-Sant'Anna</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fries</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Stertz</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients</article-title>
<source/>J Psychiatr Res
          <year>2009</year>
<volume>43</volume>
<fpage>1171</fpage>
<lpage>1174</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2009.04.002</pub-id>
<pub-id pub-id-type="pmid">19473667</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandes</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Gama</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Ceresér</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</name>
<name>
<surname>Fries</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Colpo</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis</article-title>
<source/>J Psychiatr Res
          <year>2011</year>
<volume>45</volume>
<fpage>995</fpage>
<lpage>1004</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2011.03.002</pub-id>
<pub-id pub-id-type="pmid">21550050</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandes</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Berk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Turck</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Steiner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gonçalves</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis</article-title>
<source/>Mol Psychiatry
          <year>2013</year>
<volume>19</volume>
<fpage>749</fpage>
<lpage>751</lpage>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandes</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Steiner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Berk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Molendijk</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Gonzalez-Pinto</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Turck</surname>
<given-names>CW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications</article-title>
<source/>Mol Psychiatry
          <year>2015</year>
<volume>20</volume>
<fpage>1108</fpage>
<lpage>1119</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2014.117</pub-id>
<pub-id pub-id-type="pmid">25266124</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barron</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gartlon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Atkinson</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Pardon</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>A state of delirium: deciphering the effect of inflammation on tau pathology in Alzheimer’s disease</article-title>
<source/>Exp Gerontol
          <year>2017</year>
<volume>94</volume>
<fpage>103</fpage>
<lpage>107</lpage>
<pub-id pub-id-type="doi">10.1016/j.exger.2016.12.006</pub-id>
<pub-id pub-id-type="pmid">27979768</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Donovan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ahmadian</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Neylan</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Pacult</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Edmondson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>BE</given-names>
</name>
</person-group>
<article-title>Current posttraumatic stress disorder and exaggerated threat sensitivity associated with elevated inflammation in the Mind Your Heart Study</article-title>
<source/>Brain Behav Immun
          <year>2017</year>
<volume>60</volume>
<fpage>198</fpage>
<lpage>205</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2016.10.014</pub-id>
<pub-id pub-id-type="pmid">27765647</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirkpatrick</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>BJ</given-names>
</name>
</person-group>
<article-title>Inflammation and schizophrenia</article-title>
<source/>Schizophr Bull
          <year>2013</year>
<volume>39</volume>
<fpage>1174</fpage>
<lpage>1179</lpage>
<pub-id pub-id-type="doi">10.1093/schbul/sbt141</pub-id>
<pub-id pub-id-type="pmid">24072812</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandes</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Steiner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bernstein</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Dodd</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pasco</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Dean</surname>
<given-names>OM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications</article-title>
<source/>Mol Psychiatry
          <year>2016</year>
<volume>21</volume>
<fpage>554</fpage>
<lpage>564</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2015.87</pub-id>
<pub-id pub-id-type="pmid">26169974</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madore</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Leyrolle</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Lacabanne</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Benmamar-Badel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Joffre</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nadjar</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuroinflammation in autism: plausible role of maternal inflammation, dietary omega 3, and microbiota</article-title>
<source/>Neural Plast
          <year>2016</year>
<volume>2016</volume>
<fpage>3597209</fpage>
<pub-id pub-id-type="doi">10.1155/2016/3597209</pub-id>
<pub-id pub-id-type="pmid">27840741</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Virgilio</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Greco</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fabbrini</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Inghilleri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rizzo</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Gallo</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Parkinson’s disease: autoimmunity and neuroinflammation</article-title>
<source/>Autoimmun Rev
          <year>2016</year>
<volume>15</volume>
<fpage>1005</fpage>
<lpage>1011</lpage>
<pub-id pub-id-type="doi">10.1016/j.autrev.2016.07.022</pub-id>
<pub-id pub-id-type="pmid">27497913</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hong</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Banks</surname>
<given-names>WA</given-names>
</name>
</person-group>
<article-title>Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications</article-title>
<source/>Brain Behav Immun
          <year>2015</year>
<volume>45</volume>
<fpage>1</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2014.10.008</pub-id>
<pub-id pub-id-type="pmid">25449672</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKee</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Lukens</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Emerging roles for the immune system in traumatic brain injury</article-title>
<source/>Front Immunol
          <year>2016</year>
<volume>7</volume>
<fpage>556</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2016.00556</pub-id>
<pub-id pub-id-type="pmid">27994591</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Selmi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Barin</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>NR</given-names>
</name>
</person-group>
<article-title>Current trends in autoimmunity and the nervous system</article-title>
<source/>J Autoimmun
          <year>2016</year>
<volume>75</volume>
<fpage>20</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaut.2016.08.005</pub-id>
<pub-id pub-id-type="pmid">27545842</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ransohoff</surname>
<given-names>RM</given-names>
</name>
</person-group>
<article-title>How neuroinflammation contributes to neurodegeneration</article-title>
<source/>Science
          <year>2016</year>
<volume>353</volume>
<fpage>777</fpage>
<lpage>783</lpage>
<pub-id pub-id-type="doi">10.1126/science.aag2590</pub-id>
<pub-id pub-id-type="pmid">27540165</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Jacka</surname>
<given-names>FN</given-names>
</name>
<name>
<surname>O’Neil</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pasco</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Moylan</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>So depression is an inflammatory disease, but where does the inflammation come from?</article-title>
<source/>BMC Med
          <year>2013</year>
<volume>11</volume>
<fpage>200</fpage>
<pub-id pub-id-type="doi">10.1186/1741-7015-11-200</pub-id>
<pub-id pub-id-type="pmid">24228900</pub-id>
</element-citation>
</ref>
<ref id="CR98">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leonard</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Maes</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression</article-title>
<source/>Neurosci Biobehav Rev
          <year>2012</year>
<volume>36</volume>
<fpage>764</fpage>
<lpage>785</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2011.12.005</pub-id>
<pub-id pub-id-type="pmid">22197082</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandes</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Steiner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Molendijk</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Dodd</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nardin</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gonçalves</surname>
<given-names>CA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>C-reactive protein concentrations across the mood spectrum in bipolar disorder: a systematic review and meta-analysis</article-title>
<source/>Lancet Psychiatry
          <year>2016</year>
<volume>3</volume>
<fpage>1147</fpage>
<lpage>1156</lpage>
<pub-id pub-id-type="doi">10.1016/S2215-0366(16)30370-4</pub-id>
<pub-id pub-id-type="pmid">27838212</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Slyepchenko</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Maes</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Köhler</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Quevedo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Alves</surname>
<given-names>GS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>T helper 17 cells may drive neuroprogression in major depressive disorder: proposal of an integrative model</article-title>
<source/>Neurosci Biobehav Rev
          <year>2016</year>
<volume>64</volume>
<fpage>83</fpage>
<lpage>100</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2016.02.002</pub-id>
<pub-id pub-id-type="pmid">26898639</pub-id>
</element-citation>
</ref>
<ref id="CR101">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andreazza</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Kauer-Sant’anna</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Frey</surname>
<given-names>BN</given-names>
</name>
<name>
<surname>Bond</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Kapczinski</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>LT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxidative stress markers in bipolar disorder: a meta-analysis</article-title>
<source/>J Affect Disord
          <year>2008</year>
<volume>111</volume>
<fpage>135</fpage>
<lpage>144</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2008.04.013</pub-id>
<pub-id pub-id-type="pmid">18539338</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dowlati</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Herrmann</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Swardfager</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sham</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Reim</surname>
<given-names>EK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A meta-analysis of cytokines in major depression</article-title>
<source/>Biol Psychiatry
          <year>2010</year>
<volume>67</volume>
<fpage>446</fpage>
<lpage>457</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2009.09.033</pub-id>
<pub-id pub-id-type="pmid">20015486</pub-id>
</element-citation>
</ref>
<ref id="CR103">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Köhler</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Freitas</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Maes</surname>
<given-names>M</given-names>
</name>
<name>
<surname>de Andrade</surname>
<given-names>NQ</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Fernandes</surname>
<given-names>BS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies</article-title>
<source/>Acta Psychiatr Scand
          <year>2017</year>
<volume>135</volume>
<fpage>373</fpage>
<lpage>387</lpage>
<pub-id pub-id-type="doi">10.1111/acps.12698</pub-id>
<pub-id pub-id-type="pmid">28122130</pub-id>
</element-citation>
</ref>
<ref id="CR104">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hannestad</surname>
<given-names>J</given-names>
</name>
<name>
<surname>DellaGioia</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bloch</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis</article-title>
<source/>Neuropsychopharmacology
          <year>2011</year>
<volume>36</volume>
<fpage>2452</fpage>
<lpage>2459</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2011.132</pub-id>
<pub-id pub-id-type="pmid">21796103</pub-id>
</element-citation>
</ref>
<ref id="CR105">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eller</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Vasar</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Shlik</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Maron</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Pro-inflammatory cytokines and treatment response to escitaloprsam in major depressive disorder</article-title>
<source/>Prog Neuropsychopharmacology Biol Psychiatry
          <year>2008</year>
<volume>32</volume>
<fpage>445</fpage>
<lpage>450</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2007.09.015</pub-id>
</element-citation>
</ref>
<ref id="CR106">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasco</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Pasco</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Jacka</surname>
<given-names>FN</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Henry</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Nicholson</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Kotowicz</surname>
<given-names>MA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression</article-title>
<source/>Psychother Psychosom
          <year>2010</year>
<volume>79</volume>
<fpage>323</fpage>
<lpage>325</lpage>
<pub-id pub-id-type="doi">10.1159/000319530</pub-id>
<pub-id pub-id-type="pmid">20689351</pub-id>
</element-citation>
</ref>
<ref id="CR107">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valkanova</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Ebmeier</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Allan</surname>
<given-names>CL</given-names>
</name>
</person-group>
<article-title>CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies</article-title>
<source/>J Affect Disord
          <year>2013</year>
<volume>150</volume>
<fpage>736</fpage>
<lpage>744</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2013.06.004</pub-id>
<pub-id pub-id-type="pmid">23870425</pub-id>
</element-citation>
</ref>
<ref id="CR108">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wium-Andersen</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Oørsted</surname>
<given-names>DD</given-names>
</name>
<name>
<surname>Nordestgaard</surname>
<given-names>BG</given-names>
</name>
</person-group>
<article-title>Elevated C-reactive protein, depression, somatic diseases, and all-cause mortality: a mendelian randomization study</article-title>
<source/>Biol Psychiatry
          <year>2014</year>
<volume>76</volume>
<fpage>249</fpage>
<lpage>257</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2013.10.009</pub-id>
<pub-id pub-id-type="pmid">24246360</pub-id>
</element-citation>
</ref>
<ref id="CR109">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raison</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Rutherford</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Woolwine</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Shuo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schettler</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Drake</surname>
<given-names>DF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression</article-title>
<source/>JAMA Psychiat
          <year>2013</year>
<volume>70</volume>
<fpage>31</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.1001/2013.jamapsychiatry.4</pub-id>
</element-citation>
</ref>
<ref id="CR110">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Makino</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kitano</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hirohashi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Takasuna</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Enhancement of immobility in mouse forced swimming test by treatment with human interferon</article-title>
<source/>Eur J Pharmacol
          <year>1998</year>
<volume>356</volume>
<fpage>1</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1016/S0014-2999(98)00474-9</pub-id>
<pub-id pub-id-type="pmid">9761417</pub-id>
</element-citation>
</ref>
<ref id="CR111">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Makino</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kitano</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Komiyama</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Takasuna</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Human interferon-alpha increases immobility in the forced swimming test in rats</article-title>
<source/>Psychopharmacology (Berl)
          <year>2000</year>
<volume>148</volume>
<fpage>106</fpage>
<lpage>110</lpage>
<pub-id pub-id-type="doi">10.1007/s002130050031</pub-id>
<pub-id pub-id-type="pmid">10663424</pub-id>
</element-citation>
</ref>
<ref id="CR112">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ping</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Shang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>5-HT(1A) receptor and apoptosis contribute to interferon-α-induced ‘depressive-like’ behavior in mice</article-title>
<source/>Neurosci Lett
          <year>2012</year>
<volume>514</volume>
<fpage>173</fpage>
<lpage>178</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2012.02.087</pub-id>
<pub-id pub-id-type="pmid">22414862</pub-id>
</element-citation>
</ref>
<ref id="CR113">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fischer</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Eskelund</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Budac</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Tillmann</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Liebenberg</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Elfving</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Interferon-alpha treatment induces depression-like behaviour accompanied by elevated hippocampal quinolinic acid levels in rats</article-title>
<source/>Behav Brain Res
          <year>2015</year>
<volume>293</volume>
<fpage>166</fpage>
<lpage>172</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2015.07.015</pub-id>
<pub-id pub-id-type="pmid">26205824</pub-id>
</element-citation>
</ref>
<ref id="CR114">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Müller</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Schwarz</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Dehning</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Douhe</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cerovecki</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Goldstein-Müller</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine</article-title>
<source/>Mol Psychiatry
          <year>2006</year>
<volume>11</volume>
<fpage>680</fpage>
<lpage>684</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4001805</pub-id>
<pub-id pub-id-type="pmid">16491133</pub-id>
</element-citation>
</ref>
<ref id="CR115">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Köhler</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Benros</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Nordentoft</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Farkouh</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Iyengar</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Mors</surname>
<given-names>O</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects</article-title>
<source/>JAMA Psychiat
          <year>2014</year>
<volume>71</volume>
<fpage>1381</fpage>
<lpage>1391</lpage>
<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2014.1611</pub-id>
</element-citation>
</ref>
<ref id="CR116">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uher</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Carver</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Power</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Mors</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Maier</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Rietschel</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Non-steroidal anti-inflammatory drugs and efficacy of antidepressants in major depressive disorder</article-title>
<source/>Psychol Med
          <year>2012</year>
<volume>42</volume>
<fpage>2027</fpage>
<lpage>2035</lpage>
<pub-id pub-id-type="doi">10.1017/S0033291712000190</pub-id>
<pub-id pub-id-type="pmid">22391106</pub-id>
</element-citation>
</ref>
<ref id="CR117">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tyring</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gottlieb</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Papp</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Leonardi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase III trial</article-title>
<source/>Lancet
          <year>2006</year>
<volume>367</volume>
<fpage>29</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(05)67763-X</pub-id>
<pub-id pub-id-type="pmid">16399150</pub-id>
</element-citation>
</ref>
<ref id="CR118">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Menter</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Augustin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Signorovitch</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>EQ</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>SR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial</article-title>
<source/>J Am Acad Dermatol
          <year>2010</year>
<volume>62</volume>
<fpage>812</fpage>
<lpage>818</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaad.2009.07.022</pub-id>
<pub-id pub-id-type="pmid">20219265</pub-id>
</element-citation>
</ref>
<ref id="CR119">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ertenli</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ozer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kiraz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Apras</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Akdogan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Karadag</surname>
<given-names>O</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Infliximab, a TNF-alpha antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level</article-title>
<source/>Rheumatol Int
          <year>2012</year>
<volume>32</volume>
<fpage>323</fpage>
<lpage>330</lpage>
<pub-id pub-id-type="doi">10.1007/s00296-010-1616-x</pub-id>
<pub-id pub-id-type="pmid">21079965</pub-id>
</element-citation>
</ref>
<ref id="CR120">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Langley</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schenkel</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Szapary</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>MC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial</article-title>
<source/>J Am Acad Dermatol
          <year>2010</year>
<volume>63</volume>
<fpage>457</fpage>
<lpage>465</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaad.2009.09.014</pub-id>
<pub-id pub-id-type="pmid">20462664</pub-id>
</element-citation>
</ref>
<ref id="CR121">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Demirtaş</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bayramgürler</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Balci</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Utkan</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Chronic administration of infliximab (TNF-α inhibitor) decreases depression and anxiety-like behaviour in rat model of chronic mild stress</article-title>
<source/>Basic Clin Pharmacol Toxicol
          <year>2013</year>
<volume>112</volume>
<fpage>335</fpage>
<lpage>340</lpage>
<pub-id pub-id-type="doi">10.1111/bcpt.12037</pub-id>
<pub-id pub-id-type="pmid">23167806</pub-id>
</element-citation>
</ref>
<ref id="CR122">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mendlewicz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kriwin</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Oswald</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Souery</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Alboni</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Brunello</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study</article-title>
<source/>Int Clin Psychopharmacol
          <year>2006</year>
<volume>21</volume>
<fpage>227</fpage>
<lpage>231</lpage>
<pub-id pub-id-type="doi">10.1097/00004850-200607000-00005</pub-id>
<pub-id pub-id-type="pmid">16687994</pub-id>
</element-citation>
</ref>
<ref id="CR123">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fond</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hamdani</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kapczinski</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Boukouaci</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Drancourt</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Dargel</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effectiveness and tolerance of anti-inflammatory drugs’ add-on therapy in major mental disorders: a systematic qualitative review</article-title>
<source/>Acta Psychiatr Scand
          <year>2014</year>
<volume>129</volume>
<fpage>163</fpage>
<lpage>179</lpage>
<pub-id pub-id-type="doi">10.1111/acps.12211</pub-id>
<pub-id pub-id-type="pmid">24215721</pub-id>
</element-citation>
</ref>
<ref id="CR124">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dean</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Drexhage</surname>
<given-names>H</given-names>
</name>
<name>
<surname>McNeil</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Moylan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>O’Neil</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness</article-title>
<source/>BMC Med
          <year>2013</year>
<volume>11</volume>
<fpage>74</fpage>
<pub-id pub-id-type="doi">10.1186/1741-7015-11-74</pub-id>
<pub-id pub-id-type="pmid">23506529</pub-id>
</element-citation>
</ref>
<ref id="CR125">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Almeida</surname>
<given-names>OP</given-names>
</name>
<name>
<surname>Flicker</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yeap</surname>
<given-names>BB</given-names>
</name>
<name>
<surname>Alfonso</surname>
<given-names>H</given-names>
</name>
<name>
<surname>McCaul</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hankey</surname>
<given-names>GJ</given-names>
</name>
</person-group>
<article-title>Aspirin decreases the risk of depression in older men with high plasma homocysteine</article-title>
<source/>Transl Psychiatry
          <year>2012</year>
<volume>2</volume>
<pub-id pub-id-type="doi">10.1038/tp.2012.79</pub-id>
<pub-id pub-id-type="pmid">22872164</pub-id>
</element-citation>
</ref>
<ref id="CR126">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dean</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Cotton</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Gama</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Kapczinski</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Fernandes</surname>
<given-names>BS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial</article-title>
<source/>J Affect Disord
          <year>2011</year>
<volume>135</volume>
<fpage>389</fpage>
<lpage>394</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2011.06.005</pub-id>
<pub-id pub-id-type="pmid">21719110</pub-id>
</element-citation>
</ref>
<ref id="CR127">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dean</surname>
<given-names>OM</given-names>
</name>
<name>
<surname>Cotton</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Jeavons</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tanious</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kohlmann</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial</article-title>
<source/>J Clin Psychiatry
          <year>2014</year>
<volume>75</volume>
<fpage>628</fpage>
<lpage>636</lpage>
<pub-id pub-id-type="doi">10.4088/JCP.13m08454</pub-id>
<pub-id pub-id-type="pmid">25004186</pub-id>
</element-citation>
</ref>
<ref id="CR128">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandes</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Dean</surname>
<given-names>OM</given-names>
</name>
<name>
<surname>Dodd</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Malhi</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Berk</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>N-acetylcysteine in depressive symptoms and functionality: a systematic review and meta-analysis</article-title>
<source/>J Clin Psychiatry
          <year>2016</year>
<volume>77</volume>
<fpage>e457</fpage>
<lpage>e466</lpage>
<pub-id pub-id-type="doi">10.4088/JCP.15r09984</pub-id>
<pub-id pub-id-type="pmid">27137430</pub-id>
</element-citation>
</ref>
<ref id="CR129">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wood</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Mΰller</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Eckert</surname>
<given-names>GP</given-names>
</name>
</person-group>
<article-title>Statins and neuroprotection: basic pharmacology needed</article-title>
<source/>Mol Neurobiol
          <year>2014</year>
<volume>50</volume>
<fpage>214</fpage>
<lpage>220</lpage>
<pub-id pub-id-type="doi">10.1007/s12035-014-8647-3</pub-id>
<pub-id pub-id-type="pmid">24474514</pub-id>
</element-citation>
</ref>
<ref id="CR130">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zhuang</surname>
<given-names>QK</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>YY</given-names>
</name>
</person-group>
<article-title>Statins excert neuroprotection on cerebral ischemia independent of their lipid-lowering action: the potential molecular mechanisms</article-title>
<source/>Eur Rev Med Pharmacol Sci
          <year>2014</year>
<volume>18</volume>
<fpage>1113</fpage>
<lpage>1126</lpage>
<pub-id pub-id-type="pmid">24817284</pub-id>
</element-citation>
</ref>
<ref id="CR131">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malfitano</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Marasco</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Proto</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Laezza</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gazzerro</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bifulco</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Statins in neurological disorders: an overview and update</article-title>
<source/>Pharmacol Res
          <year>2014</year>
<volume>88</volume>
<fpage>74</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="doi">10.1016/j.phrs.2014.06.007</pub-id>
<pub-id pub-id-type="pmid">24954580</pub-id>
</element-citation>
</ref>
<ref id="CR132">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Neil</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sanna</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Redlich</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sanderson</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jacka</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>LJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The impact of statins on psychological wellbeing: a systematic review and meta-analysis</article-title>
<source/>BMC Med
          <year>2012</year>
<volume>10</volume>
<fpage>154</fpage>
<pub-id pub-id-type="doi">10.1186/1741-7015-10-154</pub-id>
<pub-id pub-id-type="pmid">23206308</pub-id>
</element-citation>
</ref>
<ref id="CR133">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young-Xu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Ravid</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Blatt</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>Long-term statin use and psychological well-being</article-title>
<source/>J Am Coll Cardiol
          <year>2003</year>
<volume>42</volume>
<fpage>690</fpage>
<lpage>697</lpage>
<pub-id pub-id-type="doi">10.1016/S0735-1097(03)00785-X</pub-id>
<pub-id pub-id-type="pmid">12932603</pub-id>
</element-citation>
</ref>
<ref id="CR134">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salagre</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fernandes</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Dodd</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Brownstein</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Berk</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Statins for the treatment of depression: a meta-analysis of randomized, double-blind, placebo-controlled trials</article-title>
<source/>J Affect Disord
          <year>2016</year>
<volume>200</volume>
<fpage>235</fpage>
<lpage>242</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2016.04.047</pub-id>
<pub-id pub-id-type="pmid">27148902</pub-id>
</element-citation>
</ref>
<ref id="CR135">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Appleton</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Ness</surname>
<given-names>AR</given-names>
</name>
</person-group>
<article-title>Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood</article-title>
<source/>Am J Clin Nutr
          <year>2010</year>
<volume>91</volume>
<fpage>757</fpage>
<lpage>770</lpage>
<pub-id pub-id-type="doi">10.3945/ajcn.2009.28313</pub-id>
<pub-id pub-id-type="pmid">20130098</pub-id>
</element-citation>
</ref>
<ref id="CR136">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rigat</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hubert</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Alhenc-Gelas</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cambien</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Corvol</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Soubrier</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels</article-title>
<source/>J Clin Invest
          <year>1990</year>
<volume>86</volume>
<fpage>1343</fpage>
<lpage>1346</lpage>
<pub-id pub-id-type="doi">10.1172/JCI114844</pub-id>
<pub-id pub-id-type="pmid">1976655</pub-id>
</element-citation>
</ref>
<ref id="CR137">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>The I/D polymorphism of angiotensin-converting enzyme gene in major depressive disorder and therapeutic outcome: a case-control study and meta-analysis</article-title>
<source/>J Affect Disord
          <year>2012</year>
<volume>136</volume>
<fpage>971</fpage>
<lpage>978</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2011.08.019</pub-id>
<pub-id pub-id-type="pmid">22036796</pub-id>
</element-citation>
</ref>
<ref id="CR138">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>López-León</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Janssens</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>González-Zuloeta Ladd</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Del-Favero</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Claes</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Oostra</surname>
<given-names>BA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Meta-analyses of genetic studies on major depressive disorder</article-title>
<source/>Mol Psychiatry
          <year>2008</year>
<volume>13</volume>
<fpage>772</fpage>
<lpage>785</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4002088</pub-id>
<pub-id pub-id-type="pmid">17938638</pub-id>
</element-citation>
</ref>
<ref id="CR139">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baghai</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Binder</surname>
<given-names>EB</given-names>
</name>
<name>
<surname>Schule</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Salyakina</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Eser</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lucae</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Polymorphisms in the angiotensin-converting enzyme gene are associated with unipolar depression, ACE activity and hypercortisolism</article-title>
<source/>Mol Psychiatry
          <year>2006</year>
<volume>11</volume>
<fpage>1003</fpage>
<lpage>1015</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4001884</pub-id>
<pub-id pub-id-type="pmid">16924268</pub-id>
</element-citation>
</ref>
<ref id="CR140">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Angunsri</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sritharathikhun</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Suttirat</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tencomnao</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Association of angiotensin-converting enzyme gene promoter single nucleotide polymorphisms and haplotype with major depression in a northeastern Thai population</article-title>
<source/>J Renin Angiotensin Aldosterone Syst
          <year>2009</year>
<volume>10</volume>
<fpage>179</fpage>
<lpage>184</lpage>
<pub-id pub-id-type="doi">10.1177/1470320309344151</pub-id>
<pub-id pub-id-type="pmid">19713413</pub-id>
</element-citation>
</ref>
<ref id="CR141">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Firouzabadi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Shafiei</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bahramali</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ebrahimi</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Bakhshandeh</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tajik</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Association of angiotensin-converting enzyme (ACE) gene polymorphism with elevated serum ACE activity and major depression in an Iranian population</article-title>
<source/>Psychiatry Res
          <year>2012</year>
<volume>200</volume>
<fpage>336</fpage>
<lpage>342</lpage>
<pub-id pub-id-type="doi">10.1016/j.psychres.2012.05.002</pub-id>
<pub-id pub-id-type="pmid">22688325</pub-id>
</element-citation>
</ref>
<ref id="CR142">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ancelin</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Carrière</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Scali</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ritchie</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chaudieu</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ryan</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Angiotensin-converting enzyme gene variants are associated with both cortisol secretion and late-life depression</article-title>
<source/>Transl Psychiatry
          <year>2013</year>
<volume>3</volume>
<pub-id pub-id-type="doi">10.1038/tp.2013.95</pub-id>
<pub-id pub-id-type="pmid">24193727</pub-id>
</element-citation>
</ref>
<ref id="CR143">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bondy</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Baghai</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Zill</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Schule</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Eser</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Deiml</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic variants in the angiotensin I-converting-enzyme (ACE) and angiotensin II receptor (AT1) gene and clinical outcome in depression</article-title>
<source/>Prog Neuropsychopharmacology Biol Psychiatry
          <year>2005</year>
<volume>29</volume>
<fpage>1094</fpage>
<lpage>1099</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2005.03.015</pub-id>
</element-citation>
</ref>
<ref id="CR144">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kondo</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Speer</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Krishnan</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>McQuoid</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Slifer</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Pieper</surname>
<given-names>CF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of AGTR1 with 18-month treatment outcome in late-life depression</article-title>
<source/>Am J Geriatr Psychiatry
          <year>2007</year>
<volume>15</volume>
<fpage>564</fpage>
<lpage>572</lpage>
<pub-id pub-id-type="doi">10.1097/JGP.0b013e31805470a4</pub-id>
<pub-id pub-id-type="pmid">17586781</pub-id>
</element-citation>
</ref>
<ref id="CR145">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zill</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Baghai</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Schüle</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Born</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Früstück</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Büttner</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>DNA methylation analysis of the angiotensin converting enzyme (ACE) gene in major depression</article-title>
<source/>PLoS One
          <year>2012</year>
<volume>7</volume>
<pub-id pub-id-type="doi">10.1371/journal.pone.0040479</pub-id>
<pub-id pub-id-type="pmid">22808171</pub-id>
</element-citation>
</ref>
<ref id="CR146">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bahramali</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Firouzabadi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Yavarian</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Shayesteh</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Erfani</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Shoushtari</surname>
<given-names>AA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Influence of ACE gene on differential response to sertraline versus fluoxetine in patients with major depression: a randomized controlled trial</article-title>
<source/>Eur J Clin Pharmacol
          <year>2016</year>
<volume>72</volume>
<fpage>1059</fpage>
<lpage>1064</lpage>
<pub-id pub-id-type="doi">10.1007/s00228-016-2079-0</pub-id>
<pub-id pub-id-type="pmid">27262302</pub-id>
</element-citation>
</ref>
<ref id="CR147">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baghai</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Schule</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zill</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Deiml</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Eser</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zwanzger</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The angiotensin I converting enzyme insertion/deletion polymorphism influences therapeutic outcome in major depressed women, but not in men</article-title>
<source/>Neurosci Lett
          <year>2004</year>
<volume>363</volume>
<fpage>38</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2004.03.052</pub-id>
<pub-id pub-id-type="pmid">15157992</pub-id>
</element-citation>
</ref>
<ref id="CR148">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hou</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>G</given-names>
</name>
<name>
<surname>You</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The D-allele of ACE insertion/deletion polymorphism is associated with regional white matter volume changes and cognitive impairment in remitted geriatric depression</article-title>
<source/>Neurosci Lett
          <year>2010</year>
<volume>479</volume>
<fpage>262</fpage>
<lpage>266</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2010.05.076</pub-id>
<pub-id pub-id-type="pmid">20639003</pub-id>
</element-citation>
</ref>
<ref id="CR149">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>F</given-names>
</name>
<name>
<surname>You</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Abnormal default-mode network in angiotensin converting enzyme D allele carriers with remitted geriatric depression</article-title>
<source/>Behav Brain Res
          <year>2012</year>
<volume>230</volume>
<fpage>325</fpage>
<lpage>332</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2012.02.011</pub-id>
<pub-id pub-id-type="pmid">22348891</pub-id>
</element-citation>
</ref>
<ref id="CR150">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fudalej</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fudalej</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kostrzewa</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kuźniar</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Franaszczyk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wojnar</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Angiotensin-converting enzyme polymorphism and completed suicide: an association in caucasians and evidence for a link with a method of self-injury</article-title>
<source/>Neuropsychobiology
          <year>2009</year>
<volume>59</volume>
<fpage>151</fpage>
<lpage>158</lpage>
<pub-id pub-id-type="doi">10.1159/000218077</pub-id>
<pub-id pub-id-type="pmid">19439995</pub-id>
</element-citation>
</ref>
<ref id="CR151">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sparks</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Hunsaker</surname>
<given-names>JC</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Amouyel</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Malafosse</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bellivier</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Leboyer</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Angiotensin I-converting enzyme I/D polymorphism and suicidal behaviors</article-title>
<source/>Am J Med Genet B Neuropsychiatr Genet
          <year>2009</year>
<volume>150B</volume>
<fpage>290</fpage>
<lpage>294</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.30793</pub-id>
<pub-id pub-id-type="pmid">18521860</pub-id>
</element-citation>
</ref>
<ref id="CR152">
<label>152.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sonino</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tomba</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Genesia</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Bertello</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mulatero</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Veglio</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Psychological assessment of primary aldosteronism: a controlled study</article-title>
<source/>J Clin Endocrinol Metab
          <year>2011</year>
<volume>96</volume>
<fpage>E878</fpage>
<lpage>E883</lpage>
<pub-id pub-id-type="doi">10.1210/jc.2010-2723</pub-id>
<pub-id pub-id-type="pmid">21389142</pub-id>
</element-citation>
</ref>
<ref id="CR153">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Künzel</surname>
<given-names>HE</given-names>
</name>
</person-group>
<article-title>Psychopathological symptoms in patients with primary hyperaldosteronism - Possible pathways</article-title>
<source/>Horm Metab Res
          <year>2012</year>
<volume>44</volume>
<fpage>202</fpage>
<lpage>207</lpage>
<pub-id pub-id-type="doi">10.1055/s-0032-1301921</pub-id>
<pub-id pub-id-type="pmid">22351473</pub-id>
</element-citation>
</ref>
<ref id="CR154">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hlavacova</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Wes</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Ondrejcakova</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Flynn</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Poundstone</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Babic</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder</article-title>
<source/>Int J Neuropsychopharmacol
          <year>2012</year>
<volume>15</volume>
<fpage>247</fpage>
<lpage>265</lpage>
<pub-id pub-id-type="doi">10.1017/S1461145711000368</pub-id>
<pub-id pub-id-type="pmid">21375792</pub-id>
</element-citation>
</ref>
<ref id="CR155">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hlavacova</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Jezova</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Chronic treatment with the mineralocorticoid hormone aldosterone results in increased anxiety-like behavior</article-title>
<source/>Horm Behav
          <year>2008</year>
<volume>54</volume>
<fpage>90</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="doi">10.1016/j.yhbeh.2008.02.004</pub-id>
<pub-id pub-id-type="pmid">18377905</pub-id>
</element-citation>
</ref>
<ref id="CR156">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morris</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Na</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Grippo</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>AK</given-names>
</name>
</person-group>
<article-title>The effects of deoxycorticosterone-induced sodium appetite on hedonic behaviors in the rat</article-title>
<source/>Behav Neurosci
          <year>2006</year>
<volume>120</volume>
<fpage>571</fpage>
<lpage>579</lpage>
<pub-id pub-id-type="doi">10.1037/0735-7044.120.3.571</pub-id>
<pub-id pub-id-type="pmid">16768609</pub-id>
</element-citation>
</ref>
<ref id="CR157">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hlavacova</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Jezova</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Effect of single treatment with the antihypertensive drug eplerenone on hormone levels and anxiety-like behaviour in rats</article-title>
<source/>Endocr Regul
          <year>2008</year>
<volume>42</volume>
<fpage>147</fpage>
<lpage>153</lpage>
<pub-id pub-id-type="pmid">18999902</pub-id>
</element-citation>
</ref>
<ref id="CR158">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Büttner</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jezova</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Konrad</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kircher</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Murck</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Target-based biomarker selection - mineralocorticoid receptor-related biomarkers and treatment outcome in major depression</article-title>
<source/>J Psychiatr Res
          <year>2015</year>
<volume>66–7</volume>
<fpage>24</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2015.04.012</pub-id>
</element-citation>
</ref>
<ref id="CR159">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Segeda</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Izakova</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hlavacova</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bednarova</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jezova</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Aldosterone concentrations in saliva reflect the duration and severity of depressive episode in a sex dependent manner</article-title>
<source/>J Psychiatr Res
          <year>2017</year>
<volume>91</volume>
<fpage>164</fpage>
<lpage>168</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2017.04.011</pub-id>
<pub-id pub-id-type="pmid">28477530</pub-id>
</element-citation>
</ref>
<ref id="CR160">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hallberg</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Westrin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Isaksson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Janelidze</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Träskman-Bendz</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Brundin</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Decreased aldosterone in the plasma of suicide attempters with major depressive disorder</article-title>
<source/>Psychiatry Res
          <year>2011</year>
<volume>187</volume>
<fpage>135</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="doi">10.1016/j.psychres.2010.07.038</pub-id>
<pub-id pub-id-type="pmid">20797799</pub-id>
</element-citation>
</ref>
<ref id="CR161">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franklin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hlavacova</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Babic</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pokusa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bermudez</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Jezova</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Aldosterone signals the onset of depressive behaviour in a female rat model of depression along with SSRI treatment resistance</article-title>
<source/>Neuroendocrinology
          <year>2015</year>
<volume>102</volume>
<fpage>274</fpage>
<lpage>287</lpage>
<pub-id pub-id-type="doi">10.1159/000431152</pub-id>
<pub-id pub-id-type="pmid">25968351</pub-id>
</element-citation>
</ref>
<ref id="CR162">
<label>162.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nierenberg</surname>
<given-names>AA</given-names>
</name>
</person-group>
<article-title>Three paths to drug discovery in psychiatry</article-title>
<source/>Am J Psychiatry
          <year>2015</year>
<volume>172</volume>
<fpage>412</fpage>
<lpage>414</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.2014.14070858</pub-id>
<pub-id pub-id-type="pmid">25930130</pub-id>
</element-citation>
</ref>
<ref id="CR163">
<label>163.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thöne-Reineke</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Steckelings</surname>
<given-names>UM</given-names>
</name>
<name>
<surname>Unger</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Angiotensin receptor blockers and cerebral protection in stroke</article-title>
<source/>J Hypertens
          <year>2006</year>
<volume>24</volume>
<fpage>S115</fpage>
<lpage>S121</lpage>
<pub-id pub-id-type="doi">10.1097/01.hjh.0000220416.07235.37</pub-id>
</element-citation>
</ref>
<ref id="CR164">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benigni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cassis</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Remuzzi</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Angiotensin II revisited: new roles in inflammation, immunology and aging</article-title>
<source/>EMBO Mol Med
          <year>2010</year>
<volume>2</volume>
<fpage>247</fpage>
<lpage>257</lpage>
<pub-id pub-id-type="doi">10.1002/emmm.201000080</pub-id>
<pub-id pub-id-type="pmid">20597104</pub-id>
</element-citation>
</ref>
<ref id="CR165">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kume</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hanyu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sakurai</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Takada</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Onuma</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Iwamoto</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer’s disease</article-title>
<source/>Geriatr Gerontol Int
          <year>2012</year>
<volume>12</volume>
<fpage>207</fpage>
<lpage>214</lpage>
<pub-id pub-id-type="doi">10.1111/j.1447-0594.2011.00746.x</pub-id>
<pub-id pub-id-type="pmid">21929736</pub-id>
</element-citation>
</ref>
<ref id="CR166">
<label>166.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Whitmer</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Kivipelto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lawler</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kazis</surname>
<given-names>LE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis</article-title>
<source/>BMJ
          <year>2010</year>
<volume>340</volume>
<fpage>b5465</fpage>
<pub-id pub-id-type="doi">10.1136/bmj.b5465</pub-id>
<pub-id pub-id-type="pmid">20068258</pub-id>
</element-citation>
</ref>
<ref id="CR167">
<label>167.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okuyama</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sakagawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sugiyama</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Fukamizu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Murakami</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Reduction of depressive-like behavior in mice lacking angiotensinogen</article-title>
<source/>Neurosci Lett
          <year>1999</year>
<volume>261</volume>
<fpage>167</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="doi">10.1016/S0304-3940(99)00002-6</pub-id>
<pub-id pub-id-type="pmid">10081975</pub-id>
</element-citation>
</ref>
<ref id="CR168">
<label>168.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giardina</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Ebert</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>Positive effects of captopril in the behavioral despair swim test</article-title>
<source/>Biol Psychiatry
          <year>1989</year>
<volume>25</volume>
<fpage>697</fpage>
<lpage>702</lpage>
<pub-id pub-id-type="doi">10.1016/0006-3223(89)90240-0</pub-id>
<pub-id pub-id-type="pmid">2647155</pub-id>
</element-citation>
</ref>
<ref id="CR169">
<label>169.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Massol</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Puech</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Captopril as an antidepressant? Effects on the learned helplessness paradigm in rats</article-title>
<source/>Biol Psychiatry
          <year>1990</year>
<volume>27</volume>
<fpage>968</fpage>
<lpage>974</lpage>
<pub-id pub-id-type="doi">10.1016/0006-3223(90)90034-Y</pub-id>
<pub-id pub-id-type="pmid">2185850</pub-id>
</element-citation>
</ref>
<ref id="CR170">
<label>170.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ayyub</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Najmi</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Akhtar</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Protective effect of irbesartan an angiotensin (AT1) receptor antagonist in unpredictable chronic mild stress induced depression in mice</article-title>
<source/>Drug Res (Stuttg)
          <year>2017</year>
<volume>67</volume>
<fpage>59</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="pmid">27756096</pub-id>
</element-citation>
</ref>
<ref id="CR171">
<label>171.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ping</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zhaochun</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Valsartan reverses depressive/anxiety-like behavior and induces hippocampal neurogenesis and expression of BDNF protein in unpredictable chronic mild stress mice</article-title>
<source/>Pharmacol Biochem Behav
          <year>2014</year>
<volume>124</volume>
<fpage>5</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1016/j.pbb.2014.05.006</pub-id>
<pub-id pub-id-type="pmid">24844704</pub-id>
</element-citation>
</ref>
<ref id="CR172">
<label>172.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aswar</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Chepurwar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shintre</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Aswar</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Telmisartan attenuates diabetes induced depression in rats</article-title>
<source/>Pharmacol Reports
          <year>2017</year>
<volume>69</volume>
<fpage>358</fpage>
<lpage>364</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharep.2016.12.004</pub-id>
</element-citation>
</ref>
<ref id="CR173">
<label>173.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saavedra</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Armando</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bregonzio</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Juorio</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Macova</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pavel</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A centrally acting, anxiolytic angiotensin II AT1 receptor antagonist prevents the isolation stress-induced decrease in cortical CRF1 receptor and benzodiazepine binding</article-title>
<source/>Neuropsychopharmacology
          <year>2006</year>
<volume>31</volume>
<fpage>1123</fpage>
<lpage>1134</lpage>
<pub-id pub-id-type="pmid">16205776</pub-id>
</element-citation>
</ref>
<ref id="CR174">
<label>174.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Llano López</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Caif</surname>
<given-names>F</given-names>
</name>
<name>
<surname>García</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fraile</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Landa</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Baiardi</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Anxiolytic-like effect of losartan injected into amygdala of the acutely stressed rats</article-title>
<source/>Pharmacol Reports
          <year>2012</year>
<volume>64</volume>
<fpage>54</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="doi">10.1016/S1734-1140(12)70730-2</pub-id>
</element-citation>
</ref>
<ref id="CR175">
<label>175.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srinivasan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Suresh</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ramanathan</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Differential anxiolytic effect of enalapril and losartan in normotensive and renal hypertensive rats</article-title>
<source/>Physiol Behav
          <year>2003</year>
<volume>78</volume>
<fpage>585</fpage>
<lpage>591</lpage>
<pub-id pub-id-type="doi">10.1016/S0031-9384(03)00036-2</pub-id>
<pub-id pub-id-type="pmid">12782212</pub-id>
</element-citation>
</ref>
<ref id="CR176">
<label>176.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Costall</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Domeney</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Gerrard</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Horovitz</surname>
<given-names>ZP</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Naylor</surname>
<given-names>RJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effects of captopril and SQ29,852 on anxiety-related behaviours in rodent and marmoset</article-title>
<source/>Pharmacol Biochem Behav
          <year>1990</year>
<volume>36</volume>
<fpage>13</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="doi">10.1016/0091-3057(90)90118-2</pub-id>
<pub-id pub-id-type="pmid">2112256</pub-id>
</element-citation>
</ref>
<ref id="CR177">
<label>177.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Golding</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Overall</surname>
<given-names>ADJ</given-names>
</name>
<name>
<surname>Gard</surname>
<given-names>PR</given-names>
</name>
</person-group>
<article-title>Strain differences and the role of AT1 receptor expression in anxiety</article-title>
<source/>Int J Mol Epidemiol Genet
          <year>2011</year>
<volume>2</volume>
<fpage>51</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="pmid">21537401</pub-id>
</element-citation>
</ref>
<ref id="CR178">
<label>178.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kangussu</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Almeida-Santos</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Moreira</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Fontes</surname>
<given-names>MAP</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>RAS</given-names>
</name>
<name>
<surname>Aguiar</surname>
<given-names>DC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reduced anxiety-like behavior in transgenic rats with chronically overproduction of angiotensin-(1-7): role of the Mas receptor</article-title>
<source/>Behav Brain Res
          <year>2017</year>
<volume>331</volume>
<fpage>193</fpage>
<lpage>198</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2017.05.026</pub-id>
<pub-id pub-id-type="pmid">28502733</pub-id>
</element-citation>
</ref>
<ref id="CR179">
<label>179.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>de Kloet</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Pati</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hiller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Pioquinto</surname>
<given-names>DJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increasing brain angiotensin converting enzyme 2 activity decreases anxiety-like behavior in male mice by activating central Mas receptors</article-title>
<source/>Neuropharmacology
          <year>2016</year>
<volume>105</volume>
<fpage>114</fpage>
<lpage>123</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.12.026</pub-id>
<pub-id pub-id-type="pmid">26767952</pub-id>
</element-citation>
</ref>
<ref id="CR180">
<label>180.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bild</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Ciobica</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Angiotensin-(1-7) central administration induces anxiolytic-like effects in elevated plus maze and decreased oxidative stress in the amygdala</article-title>
<source/>J Affect Disord
          <year>2013</year>
<volume>145</volume>
<fpage>165</fpage>
<lpage>171</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2012.07.024</pub-id>
<pub-id pub-id-type="pmid">22868060</pub-id>
</element-citation>
</ref>
<ref id="CR181">
<label>181.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Almeida-Santos</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Kangussu</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Moreira</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Aguiar</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Campagnole-Santos</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Anxiolytic- and antidepressant-like effects of angiotensin-(1-7) in hypertensive transgenic (mRen2)27 rats</article-title>
<source/>Clin Sci (Lond)
          <year>2016</year>
<volume>130</volume>
<fpage>1247</fpage>
<lpage>1255</lpage>
<pub-id pub-id-type="doi">10.1042/CS20160116</pub-id>
<pub-id pub-id-type="pmid">27129185</pub-id>
</element-citation>
</ref>
<ref id="CR182">
<label>182.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torika</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Asraf</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Roasso</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Danon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fleisher-Berkovich</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Angiotensin converting enzyme inhibitors ameliorate brain inflammation associated with microglial activation: possible implications for Alzheimer’s disease</article-title>
<source/>J Neuroimmune Pharmacol
          <year>2016</year>
<volume>11</volume>
<fpage>774</fpage>
<lpage>785</lpage>
<pub-id pub-id-type="doi">10.1007/s11481-016-9703-8</pub-id>
<pub-id pub-id-type="pmid">27562846</pub-id>
</element-citation>
</ref>
<ref id="CR183">
<label>183.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torika</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Asraf</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Danon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Apte</surname>
<given-names>RN</given-names>
</name>
<name>
<surname>Fleisher-Berkovich</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Telmisartan modulates glial activation: in vitro and in vivo studies</article-title>
<source/>PLoS One
          <year>2016</year>
<volume>11</volume>
<pub-id pub-id-type="doi">10.1371/journal.pone.0155823</pub-id>
<pub-id pub-id-type="pmid">27187688</pub-id>
</element-citation>
</ref>
<ref id="CR184">
<label>184.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torika</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Asraf</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fleisher-Berkovich</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Intranasal telmisartan ameliorates brain pathology in five familial Alzheimer’s disease mice</article-title>
<source/>Brain Behav Immun
          <year>2017</year>
<volume>64</volume>
<fpage>80</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2017.04.001</pub-id>
<pub-id pub-id-type="pmid">28385651</pub-id>
</element-citation>
</ref>
<ref id="CR185">
<label>185.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanchez-Lemus</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Murakami</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Larrayoz-Roldan</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Moughamian</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Pavel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nishioku</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Angiotensin II AT1 receptor blockade decreases lipopolysaccharide-induced inflammation in the rat adrenal gland</article-title>
<source/>Endocrinology
          <year>2008</year>
<volume>149</volume>
<fpage>5177</fpage>
<lpage>5188</lpage>
<pub-id pub-id-type="doi">10.1210/en.2008-0242</pub-id>
<pub-id pub-id-type="pmid">18556352</pub-id>
</element-citation>
</ref>
<ref id="CR186">
<label>186.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanchez-Lemus</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Benicky</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pavel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Larrayoz</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Baliova</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Angiotensin II AT1 blockade reduces the lipopolysaccharide-induced innate immune response in rat spleen</article-title>
<source/>Am J Physiol Regul Integr Comp Physiol
          <year>2009</year>
<volume>296</volume>
<fpage>R1376</fpage>
<lpage>R1384</lpage>
<pub-id pub-id-type="doi">10.1152/ajpregu.90962.2008</pub-id>
<pub-id pub-id-type="pmid">19225144</pub-id>
</element-citation>
</ref>
<ref id="CR187">
<label>187.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ambrosino</surname>
<given-names>SV</given-names>
</name>
</person-group>
<article-title>Depressive reactions associated with reserpine</article-title>
<source/>NY State J Med
          <year>1974</year>
<volume>74</volume>
<fpage>860</fpage>
<lpage>864</lpage>
</element-citation>
</ref>
<ref id="CR188">
<label>188.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bevacqua</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Fattouh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Backonja</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Depression, night terrors, and insomnia associated with long-term intrathecal clonidine therapy</article-title>
<source/>Pain Pract
          <year>2007</year>
<volume>7</volume>
<fpage>36</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1111/j.1533-2500.2007.00108.x</pub-id>
<pub-id pub-id-type="pmid">17305677</pub-id>
</element-citation>
</ref>
<ref id="CR189">
<label>189.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghanizadeh</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Insomnia, night terror, and depression related to clonidine in attention-deficit/hyperactivity disorder</article-title>
<source/>J Clin Psychopharmacol
          <year>2008</year>
<volume>28</volume>
<fpage>725</fpage>
<lpage>726</lpage>
<pub-id pub-id-type="doi">10.1097/JCP.0b013e31818ce741</pub-id>
<pub-id pub-id-type="pmid">19011458</pub-id>
</element-citation>
</ref>
<ref id="CR190">
<label>190.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldstein</surname>
<given-names>BI</given-names>
</name>
<name>
<surname>Carnethon</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Matthews</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>McIntyre</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Raghuveer</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease: a scientific statement from the American Heart Association</article-title>
<source/>Circulation
          <year>2015</year>
<volume>132</volume>
<fpage>965</fpage>
<lpage>986</lpage>
<pub-id pub-id-type="doi">10.1161/CIR.0000000000000229</pub-id>
<pub-id pub-id-type="pmid">26260736</pub-id>
</element-citation>
</ref>
<ref id="CR191">
<label>191.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scalco</surname>
<given-names>AZ</given-names>
</name>
<name>
<surname>Scalco</surname>
<given-names>MZ</given-names>
</name>
<name>
<surname>Azul</surname>
<given-names>JBS</given-names>
</name>
<name>
<surname>Lotufo</surname>
<given-names>NF</given-names>
</name>
</person-group>
<article-title>Hypertension and depression</article-title>
<source/>Clinics (Sao Paulo)
          <year>2005</year>
<volume>60</volume>
<fpage>241</fpage>
<lpage>250</lpage>
<pub-id pub-id-type="doi">10.1590/S1807-59322005000300010</pub-id>
<pub-id pub-id-type="pmid">15962086</pub-id>
</element-citation>
</ref>
<ref id="CR192">
<label>192.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johansen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Holmen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bjerkeset</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>Anxiety and depression symptoms in arterial hypertension: the influence of antihypertensive treatment. The HUNT study, Norway</article-title>
<source/>Eur J Epidemiol
          <year>2012</year>
<volume>27</volume>
<fpage>63</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="doi">10.1007/s10654-011-9641-y</pub-id>
<pub-id pub-id-type="pmid">22183137</pub-id>
</element-citation>
</ref>
<ref id="CR193">
<label>193.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huffman</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Stern</surname>
<given-names>TA</given-names>
</name>
</person-group>
<article-title>Neuropsychiatric consequences of cardiovascular medications</article-title>
<source/>Dialogues Clin Neurosci
          <year>2007</year>
<volume>9</volume>
<fpage>29</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="pmid">17506224</pub-id>
</element-citation>
</ref>
<ref id="CR194">
<label>194.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Long</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hypertension and risk of depression in the elderly: a meta-analysis of prospective cohort studies</article-title>
<source/>J Hum Hypertens
          <year>2015</year>
<volume>29</volume>
<fpage>478</fpage>
<lpage>482</lpage>
<pub-id pub-id-type="doi">10.1038/jhh.2014.112</pub-id>
<pub-id pub-id-type="pmid">25411056</pub-id>
</element-citation>
</ref>
<ref id="CR195">
<label>195.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Musselman</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Nemeroff</surname>
<given-names>CB</given-names>
</name>
</person-group>
<article-title>The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment</article-title>
<source/>Arch Gen Psychiatry
          <year>1998</year>
<volume>55</volume>
<fpage>580</fpage>
<lpage>592</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.55.7.580</pub-id>
<pub-id pub-id-type="pmid">9672048</pub-id>
</element-citation>
</ref>
<ref id="CR196">
<label>196.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hui</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Depression increases the risk of hypertension incidence</article-title>
<source/>J Hypertens
          <year>2012</year>
<volume>30</volume>
<fpage>842</fpage>
<lpage>851</lpage>
<pub-id pub-id-type="doi">10.1097/HJH.0b013e32835080b7</pub-id>
<pub-id pub-id-type="pmid">22343537</pub-id>
</element-citation>
</ref>
<ref id="CR197">
<label>197.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zubenko</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Nixon</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Mood-elevating effect of captopril in depressed patients</article-title>
<source/>Am J Psychiatry
          <year>1984</year>
<volume>141</volume>
<fpage>110</fpage>
<lpage>111</lpage>
<pub-id pub-id-type="doi">10.1176/ajp.141.10.1306</pub-id>
<pub-id pub-id-type="pmid">6318579</pub-id>
</element-citation>
</ref>
<ref id="CR198">
<label>198.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deicken</surname>
<given-names>RF</given-names>
</name>
</person-group>
<article-title>Captopril treatment of depression</article-title>
<source/>Biol Psychiatry
          <year>1986</year>
<volume>21</volume>
<fpage>1425</fpage>
<lpage>1428</lpage>
<pub-id pub-id-type="doi">10.1016/0006-3223(86)90334-3</pub-id>
<pub-id pub-id-type="pmid">3539210</pub-id>
</element-citation>
</ref>
<ref id="CR199">
<label>199.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Germain</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chouinard</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Treatment of recurrent unipolar major depression with captopril</article-title>
<source/>Biol Psychiatry
          <year>1988</year>
<volume>23</volume>
<fpage>637</fpage>
<lpage>641</lpage>
<pub-id pub-id-type="doi">10.1016/0006-3223(88)90010-8</pub-id>
<pub-id pub-id-type="pmid">3281718</pub-id>
</element-citation>
</ref>
<ref id="CR200">
<label>200.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hertzman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Adler</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Arling</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kern</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Lisinopril may augment antidepressant response</article-title>
<source/>J Clin Psychopharmacol
          <year>2005</year>
<volume>25</volume>
<fpage>618</fpage>
<lpage>620</lpage>
<pub-id pub-id-type="doi">10.1097/01.jcp.0000186736.99523.1d</pub-id>
<pub-id pub-id-type="pmid">16282855</pub-id>
</element-citation>
</ref>
<ref id="CR201">
<label>201.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rathmann</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Haastert</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Roseman</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Giani</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Cardiovascular drug prescriptions and risk of depression in diabetic patients</article-title>
<source/>J Clin Epidemiol
          <year>1999</year>
<volume>52</volume>
<fpage>1103</fpage>
<lpage>1109</lpage>
<pub-id pub-id-type="doi">10.1016/S0895-4356(99)00082-7</pub-id>
<pub-id pub-id-type="pmid">10527005</pub-id>
</element-citation>
</ref>
<ref id="CR202">
<label>202.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Pasco</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Kessing</surname>
<given-names>LV</given-names>
</name>
<name>
<surname>Quirk</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Fernandes</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Berk</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Angiotensin converting enzyme inhibitors and risk of mood disorders</article-title>
<source/>Psychother Psychosom
          <year>2016</year>
<volume>85</volume>
<fpage>250</fpage>
<lpage>252</lpage>
<pub-id pub-id-type="doi">10.1159/000444646</pub-id>
<pub-id pub-id-type="pmid">27230871</pub-id>
</element-citation>
</ref>
<ref id="CR203">
<label>203.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boal</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>McCallum</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Muir</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Touyz</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Dominiczak</surname>
<given-names>AF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Monotherapy with major antihypertensive drug classes and risk of hospital admissions for mood disorders</article-title>
<source/>Hypertension
          <year>2016</year>
<volume>68</volume>
<fpage>1132</fpage>
<lpage>1138</lpage>
<pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.116.08188</pub-id>
<pub-id pub-id-type="pmid">27733585</pub-id>
</element-citation>
</ref>
<ref id="CR204">
<label>204.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Habra</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Frasure-Smith</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Swenson</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Koszycki</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>First episode of major depressive disorder and vascular factors in coronary artery disease patients: baseline characteristics and response to antidepressant treatment in the CREATE trial</article-title>
<source/>J Psychosom Res
          <year>2010</year>
<volume>69</volume>
<fpage>133</fpage>
<lpage>141</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychores.2010.02.010</pub-id>
<pub-id pub-id-type="pmid">20624511</pub-id>
</element-citation>
</ref>
<ref id="CR205">
<label>205.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fava</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rush</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Wisniewski</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Nierenberg</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Alpert</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>McGrath</surname>
<given-names>PJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report</article-title>
<source/>Am J Psychiatry
          <year>2006</year>
<volume>163</volume>
<fpage>1161</fpage>
<lpage>1172</lpage>
<pub-id pub-id-type="doi">10.1176/ajp.2006.163.7.1161</pub-id>
<pub-id pub-id-type="pmid">16816220</pub-id>
</element-citation>
</ref>
<ref id="CR206">
<label>206.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hunter</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>Leuchter</surname>
<given-names>AF</given-names>
</name>
</person-group>
<article-title>Does prior antidepressant treatment of major depression impact brain function during current treatment?</article-title>
<source/>Eur Neuropsychopharmacol
          <year>2012</year>
<volume>22</volume>
<fpage>711</fpage>
<lpage>720</lpage>
<pub-id pub-id-type="doi">10.1016/j.euroneuro.2012.02.005</pub-id>
<pub-id pub-id-type="pmid">22445212</pub-id>
</element-citation>
</ref>
<ref id="CR207">
<label>207.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Firnhaber</surname>
<given-names>WR</given-names>
</name>
</person-group>
<article-title>Enalapril and hypertension</article-title>
<source/>Am J Psychiatry
          <year>1984</year>
<volume>141</volume>
<fpage>1012</fpage>
<lpage>1013</lpage>
<pub-id pub-id-type="doi">10.1176/ajp.141.9.1132</pub-id>
<pub-id pub-id-type="pmid">6087687</pub-id>
</element-citation>
</ref>
<ref id="CR208">
<label>208.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Croog</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Testa</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bulpitt</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>CD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The effects of antihypertensive therapy on the quality of life</article-title>
<source/>N Engl J Med
          <year>1986</year>
<volume>314</volume>
<fpage>1657</fpage>
<lpage>1664</lpage>
<pub-id pub-id-type="doi">10.1056/NEJM198606263142602</pub-id>
<pub-id pub-id-type="pmid">3520318</pub-id>
</element-citation>
</ref>
<ref id="CR209">
<label>209.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Testa</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Nackley</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Hollenberg</surname>
<given-names>NK</given-names>
</name>
</person-group>
<article-title>Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril. The Quality-of-Life Hypertension Study Group</article-title>
<source/>N Engl J Med
          <year>1993</year>
<volume>328</volume>
<fpage>907</fpage>
<lpage>913</lpage>
<pub-id pub-id-type="doi">10.1056/NEJM199304013281302</pub-id>
<pub-id pub-id-type="pmid">8446137</pub-id>
</element-citation>
</ref>
<ref id="CR210">
<label>210.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pavlatou</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Mastorakos</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lekakis</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Liatis</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Vamvakou</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zoumakis</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chronic administration of an angiotensin II receptor antagonist resets the hypothalamic–pituitary–adrenal (HPA) axis and improves the affect of patients with diabetes mellitus type 2: preliminary results</article-title>
<source/>Stress
          <year>2008</year>
<volume>11</volume>
<fpage>62</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="doi">10.1080/10253890701476621</pub-id>
<pub-id pub-id-type="pmid">17853061</pub-id>
</element-citation>
</ref>
<ref id="CR211">
<label>211.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Callender</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Hodsman</surname>
<given-names>GP</given-names>
</name>
<name>
<surname>Hutcheson</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Lever</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>JI</given-names>
</name>
</person-group>
<article-title>Mood changes during captopril therapy for hypertension. A double-blind pilot study</article-title>
<source/>Hypertension
          <year>1983</year>
<volume>5</volume>
<fpage>III90</fpage>
<lpage>III93</lpage>
<pub-id pub-id-type="doi">10.1161/01.HYP.5.5_Pt_2.III90</pub-id>
<pub-id pub-id-type="pmid">6354937</pub-id>
</element-citation>
</ref>
<ref id="CR212">
<label>212.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deary</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Capewell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hajducka</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Muir</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The effects of captopril vs atenolol on memory, information processing and mood: a double-blind crossover study</article-title>
<source/>Br J Clin Pharmacol
          <year>1991</year>
<volume>32</volume>
<fpage>347</fpage>
<lpage>353</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2125.1991.tb03910.x</pub-id>
<pub-id pub-id-type="pmid">1777372</pub-id>
</element-citation>
</ref>
<ref id="CR213">
<label>213.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Omvik</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Thaulow</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Herland</surname>
<given-names>OB</given-names>
</name>
<name>
<surname>Eide</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Midha</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>RR</given-names>
</name>
</person-group>
<article-title>Double-blind, parallel, comparative study on quality of life during treatment with amlodipine or enalapril in mild or moderate hypertensive patients: a multicentre study</article-title>
<source/>J Hypertens
          <year>1993</year>
<volume>11</volume>
<fpage>103</fpage>
<lpage>113</lpage>
<pub-id pub-id-type="doi">10.1097/00004872-199301000-00015</pub-id>
<pub-id pub-id-type="pmid">8382234</pub-id>
</element-citation>
</ref>
<ref id="CR214">
<label>214.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fletcher</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Bulpitt</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Chase</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Furberg</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Goggin</surname>
<given-names>TK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Quality of life with three antihypertensive treatments. Cilazapril, atenolol, nifedipine</article-title>
<source/>Hypertension
          <year>1992</year>
<volume>19</volume>
<fpage>499</fpage>
<lpage>507</lpage>
<pub-id pub-id-type="doi">10.1161/01.HYP.19.6.499</pub-id>
<pub-id pub-id-type="pmid">1534312</pub-id>
</element-citation>
</ref>
<ref id="CR215">
<label>215.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weir</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Elkins</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Liss</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vrecenak</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Barr</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Edelman</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension</article-title>
<source/>Clin Ther
          <year>1996</year>
<volume>18</volume>
<fpage>411</fpage>
<lpage>428</lpage>
<pub-id pub-id-type="doi">10.1016/S0149-2918(96)80022-1</pub-id>
<pub-id pub-id-type="pmid">8829017</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>